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Dissecting the role of p53-mediated metabolic regulation in tumor suppression 
Yang Ou 
The p53 tumor suppressor protein has been well-characterized for its role in inducing 
growth arrest, senescence, and apoptosis upon various types of stresses. Recently, however, roles 
of p53 have expanded beyond the canonical functions, and now include cellular processes such 
as metabolism, oxidative balance, and ferroptosis. Through RNA-seq screening, we first 
identified phosphoglycerate dehydrogenase (PHGDH), a rate-limiting enzyme in the serine 
biosynthesis pathway, as a novel metabolic target of p53. p53 suppresses PHGDH expression and 
inhibits de novo serine biosynthesis. Notably, upon serine starvation, p53-mediated cell death is 
significantly enhanced in response to Nutlin-3 treatment. Moreover, PHGDH has been 
demonstrated to be frequently amplified in human melanomas. We found that PHGDH 
overexpression significantly suppresses the apoptotic response, whereas RNAi-mediated 
knock-down of endogenous PHGDH promotes apoptosis under the same treatment. Together, our 
findings demonstrate an important role of p53 in regulating serine biosynthesis through 
suppressing PHGDH expression, and reveal serine deprivation as a novel approach to sensitize 
p53-mediated apoptotic responses in human melanoma cells.  
 
 
In addition, we also identified spermidine/spermine N
1
-acetyltransferase 1 (SAT1) as a 
novel metabolic target of p53. SAT1 is a rate-limiting enzyme in polyamine catabolism critically 
involved in the conversion of spermidine and spermine back to putrescine. Surprisingly, we 
found that activation of SAT1 expression induces lipid peroxidation and sensitizes cells to 
undergo ferroptosis upon reactive oxygen species (ROS)-induced stress, which also leads to 
suppression of tumor growth in xenograft tumor models. Notably, SAT1 expression is 
down-regulated in human tumors, and CRISPR-cas9-mediated knockout of SAT1 partially 
abrogates p53-mediated ferroptosis. Moreover, SAT1 induction is correlated with the expression 
levels of arachidonate 15-lipoxygenase (ALOX15), and SAT1-induced ferroptosis is significantly 
abrogated in the presence of PD146176, a specific inhibitor of ALOX15. Together, these data 
indicate a novel regulatory role of p53 in polyamine metabolism and provide insight into the 
regulation of p53-mediated ferroptotic responses.  
Our studies on PHGDH and SAT1 led us to the question of whether these unconventional 
functions of p53 contribute to its role as a tumor suppressor. In fact, previous view regarding the 
mechanism of p53-mediated tumor suppression, which was long thought to be growth arrest, 
apoptosis, and senescence, has recently been challenged by several knockout and knock-in 
mouse studies. Previously, we established mice (p53
3KR/3KR
) in which p53 acetylation at lysine 





mice completely lost p53-mediated cell cycle arrest, apoptosis, and senescence functions in 
response to stresses. However, unlike p53-null mice which rapidly develop spontaneous thymic 
lymphomas, all of the p53
3KR/3KR
 mice remain tumor-free, indicating that other aspects of p53 
functions are sufficient to prevent tumor formation. Notably, p53
3KR
 retains the ability to regulate 
metabolic targets including TIGAR and SAT1, as well as ferroptosis regulator SLC7A11. In this 
study, we have identified two novel acetylation sites- K98 and K136, in the mouse p53 
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 knock-in mice lost intact tumor suppression and developed 
spontaneous tumors. This suggests that p53-mediated ferroptosis may function as a critical 





 mice displayed significantly delayed 
tumorigenesis comparing with p53-null and p53
5KR/5KR





 retains the capacity to inhibit mammalian target of rapamycin (mTOR) signaling 
pathway through activating the expression of two mTOR negative regulators, Sestrin2 and 
 
 
DDIT4. Altogether, our findings underscore the extensive scope of p53 functions in metabolic 
regulation, oxidative stress response, and ferroptosis, and provide novel insights into the tumor 
suppression mechanism of p53.
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1.1 p53 tumor suppressor 
    The p53 protein is widely accepted as “cellular gatekeeper” or “the guardian of the genome” 
because of its pivotal role in suppressing tumorigenesis [1, 2]. Mutations that perturb p53 
function have been found in more than 50% of human cancers [3-6]. Germline mutation of p53, 
which results in only one functional allele of TP53 gene, is associated with Li-Fraumeni 
syndrome that confers high familiar risk of cancer [7, 8]. In addition, mice deficient in Trp53 
(gene that encodes mouse p53) are prone to develop early onset spontaneous tumors [9].  
The human p53 protein consists of an amino (N-) terminal transactivation domain (residue 
1-62), a proline rich domain (residue 63-97), a central DNA binding domain (residue 100-300), a 
tetramerization domain (residue 307-355), and carboxyl (C-) terminal regulatory domain (residue 
356-393) [10, 11]. The transactivation domain is responsible for recruiting transcriptional 
machinery and co-activators for transcription activation. The central DNA binding domain of 
p53 binds to specific DNA sequences termed “p53 responsive element” or “p53 consensus 
binding site”, which contains two decamers 5’-PuPuPuC(A/T)(T/A)GPyPyPy-3’ (Pu: purine; Py: 
pyrimidine) separated by 0-13 base pairs [12, 13]. The tetramerization domain enables p53 
subunits to form tetramer, and the C-terminal regulatory domain modulates p53 transcription 
activity through abundance of post-translational modifications [14].  
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p53 mainly functions as a transcription factor to coordinate cells to respond to a variety of 
cellular stresses, and monitor signaling pathways involved in cell cycle arrest, apoptosis, 
senescence, cellular metabolism, autophagy etc. Under physiological condition, p53 is kept at an 
extremely low level through a negative-feedback loop with Mouse Double Minute 2 (MDM2, 
human protein is often called HDM2).  MDM2 is a direct p53 transcriptional target which gets 
up-regulated upon p53 activation. It is also a p53-specific E3 ubiquitin ligase that can promote 
the ubiquitination and subsequent proteasomal degradation of p53. Upon cellular stresses such as 
DNA damage, ionizing radiation, hypoxia and oncogenic stress, p53 gets rapidly stabilized and 
activated [2, 15]. Classical models for p53 activation consist of p53 stabilization by 
ATM/ATR-mediated phosphorylation, sequence-specific DNA binding, 
co-activator/co-repressor recruitment, and subsequent transcription activation or repression of 
downstream target genes [16]. As a result, p53 coordinates cells to respond to various stresses, 
protects them from genomic instability, and ultimately, prevents tumor formation. 
1.2 Post-translational modifications of p53 
p53 is a very dynamic protein which requires a fine-tuning regulation mechanism that is 
mediated by an abundance of post-translational modifications (Figure 1.1). Post-translational 
modifications play a pivotal role in controlling p53 stability, activity, and more recently 
described, differential regulation of downstream targets. Under unstressed condition, p53 is 
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maintained at low levels through ubiquitination and subsequent proteasomal degradation [17]. 
When cells encounter stress, the ubiquitination of p53 is inhibited, and p53 is rapidly stabilized 
and activated in the nucleus mainly through phosphorylation and acetylation. This also enables 
p53 to form homotetrameric complex, which acts to bind to sequence-specific promoters of its 
downstream target genes, and recruit transcriptional machineries as well as co-activators for 
transcription activation [18]. In addition, recent findings revealed that p53 could also undergo 




Figure 1.1 Overview of p53 post-translational modifications. The p53 protein is reported to 
be modified on more than 36 amino acids by indicated modifying enzymes which include 
ubiquitination, phosphorylation, acetylation, methylation, neddylation, and sumoylation. (Figure 




    Under physiological condition, p53 protein level is tightly controlled by ubiquitin-mediated 
proteasomal degradation. Mdm2 is a major p53 E3-ubiquitin ligase and negative regulator of p53 
[22]. Mdm2 mainly targets six p53 lysine residues in the C-terminal domain for 
poly-ubiquitination and subsequent proteasomal degradation [23]; it also directly binds to p53 
transactivation domain and inhibits the transcriptional activity of p53 through blocking the 
recruitment of basic transcriptional machinery and coactivator [24].  Interestingly, p53 still 
undergoes degradation in the cells of Mdm2-null mice, suggesting the existence of 
Mdm2-independent degradation pathways. In fact, p53 can also be poly-ubiquitinated by several 
other E3-ligases, such as COP1, Pirh2, and Arf-BP1, which contribute to the overall control of 
p53 levels in the cell [25-27]. Besides proteasomal degradation, ubiquitination of p53 also plays 
a role in regulating the cellular localization of p53. p53 is found to be  mono-ubiquitinated by 
Mdm2 and other E3-ligases, and undergo nuclear export and translocation to cytoplasm, which is 
thought to play important roles in regulating apoptosis and autophagy through 
transcription-independent mechanisms [28-30].  
1.2.2 Phosphorylation 
    Phosphorylation on serine (S) or threonine (T) residues mainly in p53 N-terminal 
transactivation domain is important for the activation of p53. S15 and S20 (S18 and S23 in 
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mouse p53) are two most extensively studied phosphorylation sites in p53, which are catalyzed 
by ATM/ATR/DNA-PK and Chk1/Chk2 kinases respectively [31, 32]. Phosphorylation of p53 is 
thought to disrupt the interaction between p53 and Mdm2, and result in p53 stabilization, 
recruitment of transcriptional machinery, and subsequent p53 activation. Interestingly, mice 
bearing single S18 or S23 to alanine (A) mutation in p53 exhibit only modest effect on p53 
stability and transcriptional activity, indicating that these two phosphorylation sites have 
functional redundancy [33, 34]. However, S18/23A double-mutant p53 displayed greater defect 
in transcriptional activity, suggesting a synergetic role of these two phosphorylation sites in p53 
activation [34].  
1.2.3 Acetylation 
    Acetylation is a type of post-translational modification specifically occurs on lysine 
residues that was initially discovered in histones, and is known to have a major impact on 
transcriptional regulation [35]. p53 was later on found to be the first non-histone protein to be 
functionally regulated by acetylation and deacetylation [36, 37]. In response to stress, p53 is 
acetylated by histone acetyltransferase CBP/p300, and acetylation of p53 is known to promote 
the recruitment of cofactors and enhance target gene transcription [38]. Other p53 
acetyltransferases such as Tip60 and hMOF also play an important role in regulating p53 
transcriptional activity [39, 40]. p53 was first discovered to be acetylated at six lysine residues in 
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the C-terminal domain by CBP/p300 [36]. Interestingly, the C-terminal acetylation-deficient 
p53
6KR
 knock-in mice showed impaired p53-dependent gene expression only in embryonic stem 
cells and thymocytes, but not in embryonic fibroblasts [41]. Similarly, another knock-in study in 
p53
7KR
 mice also demonstrated that C-terminal acetylation did not affect p53-mediated cell cycle 
control and apoptosis in embryonic fibroblasts [42]. These findings suggested that the regulatory 
effects of p53 C-terminal acetylation may be cell type-specific, but does not seem to have a 
major impact on cell cycle or apoptosis control. Notably, recent studies show that p53 acetylation 
is not limited to C-terminal. Both studies have shown that p53 is acetylated at lysine K120 
located in central DNA-binding domain by hMOF and Tip60, two acetyltransferases that belong 
to the MYST family [39, 40]. The K120 lysine residue is conserved among all species that have 
functional p53 genes, suggesting that this acetylation may possess an evolutionarily conserved 
role [16]. It has been found that K120 acetylation occurs after DNA damage or oncogenic stress, 
and is required for p53 to activate proapoptotic target genes Puma and Bax [39, 43]. When K120 
acetylation is abrogated by mutating lysine to arginine, p53-mediated Puma and Bax activation 
are impaired, while the expression of Mdm2 and p21 are not affected [39]. Furthermore, loss of 
K120 acetylation does not affect p53 stability or DNA-binding either [39]. K164 is another p53 
acetylation site in the DNA-binding domain and it is acetylated by CBP/p300 [44]. Interestingly, 
loss of acetylation individually at K120, K164 or 6KR does not impair p53’s ability to activate 
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p21, suggesting that these acetylation sites may compensate each other through functional 
redundancy. However, simultaneous loss of acetylation at K120, K164, and six C-terminal lysine 
residues (p53
8KR
) completely abolishes p53’s ability to induce p21 expression and growth arrest, 
while retains the ability of p53 to bind DNA and induce Mdm2-p53 negative feedback loop [44]. 
These results also suggested that p53 acetylation is important for the regulation of promoter 
specific activation, although the molecular mechanism remains to be elucidated. Notably, p53 
can also be deacetylated by distinct deacetylases including HDAC1 and Sir2α/Sirt1, and 
deacetylation of p53 is demonstrated to repress p53-mediated transcriptional activation, growth 
arrest, and apoptosis in response to DNA damage and oxidative stress [37, 45, 46]. Overall, 
acetylation and deacetylation of p53 provides a dynamic fine-tuning mechanism that allows p53 
to activate target gene transcription in response to cellular stresses, and return to steady-state 
level after completion of DNA repair.  
1.2.4 Methylation, Neddylation and Sumoylation 
    Beside ubiquitination and acetylation, lysine residues on p53 can also undergo methylation, 
neddylation, and sumoylation, and these modifications are thought to contribute to p53 promoter 
specificity. Monomethylation of p53 at lysine K372 by methyltransferase Set7/9 has shown to 
promote p53 activity [19]. In contrast, K370 and K382 methylation by Smyd2 and Set8/PR-Set 
represses p53 activity [47, 48].  
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    Neddylation and Sumoylation are two ubiquitination-like modifications that involve in the 
addition of Neural precursor cell Expressed Developmentally Down-regulated protein 8 (Nedd8) 
and Small Ubiquitin-like Modifier (SUMO) molecules to the C-terminal lysine residues in p53. 
The exact roles of neddylation and sumoylation are not well defined. Some studies have reported 
that Mdm2-mediated neddylation on K370/372/373 and FBXO11-mediated neddylation on 
K320/321 inhibit p53 activity [20, 49]. In addition, one study demonstrated that sumoylation of 
p53 on K386 promotes the transcriptional activity of p53, while another group suggested that this 
modification induces cytoplasmic localization of p53 [21, 50].  
1.3 Classical functions of p53: growth arrest, apoptosis and senescence 
    Growth arrest, apoptosis, and senescence are the most well characterized downstream 
events in response to the p53 activation, and are thought to be the major mediators of the tumor 
suppressive function of p53.   
    Growth arrest function of p53 is predominantly mediated by its downstream target gene p21 
(WAF1). p21 binds to a number of cyclin-Cdk complexes, inhibits their kinase activity, and 
therefore, blocks cell cycle progression at G1 and S phases [51]. Interestingly, p21
-/-
 mice 
develop normally, and mouse embryonic fibroblasts (MEFs) derived from mice lacking p21 are 
partially deficient in inducing G1 arrest upon DNA damage, suggesting the existence of 
p21-indepdendent pathway that contributes to p53-mediated cell cycle arrest [52]. GADD45 and 
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14-3-3 are later characterized to be another two p53 downstream targets that play an important 
role in G2 arrest through inhibition of cyclinB-cdc2 complex [53, 54]. 
    In response to cellular stresses, p53 could induce apoptosis through both transcription 
dependent and independent pathways. p53 activates the transcription of pro-apoptotic Bcl-2 
family members including p53-upregulated modulator of apoptosis (PUMA), Bcl-2-associated X 
protein (BAX) and phorbol-12-myristate-13-acetate-induced protein 1 (NOXA) [55]. PUMA and 
NOXA bind to mitochondrial anti-apoptotic Bcl-2 family members such as Bcl-2, Bcl-XL, and 
Mcl-1, thus inhibit their interaction with Bax and lead to caspase activation and cell death [56, 
57]. In addition, p53 could directly translocate to mitochondria and trigger apoptosis through 
activation of Bcl-2 family members [58].  
    Senescence is an irreversible cell-cycle arrest in response to either telomere shortening 
during normal aging, or persistent oncogenic signaling that can be induced by p53 [59, 60]. It is 
featured by its distinctive morphology change including flattened/enlarged shape, increased 
adherence, decreased replicative capacity, and increased expression of senescence-associated 
β-galactosidase (SA-β-GAL) [61]. The key effectors of p53-mediated senescence include p21, 
plasminogen activator inhibitor-1 (PAI-1), and E2F7 [62-65]. 
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1.4. Non-canonical functions of p53 
Recently, the functions of p53 have been largely expanded beyond the classical functions of 
cell cycle arrest, apoptosis and senescence, and now include metabolism, reactive oxygen species 





Figure 1.2. p53 regulates a wide variety of cellular functions. Upon cellular stresses such as 
DNA damage, oncogenic events, or ionizing radiation, p53 is stabilized and activated to induce a 





1.4.1 Metabolism and ROS regulation 
    Metabolic alteration of tumor cells has been recognized as a hallmark of cancer. In 1926, 
Otto Warburg first described the phenomenon that unlike normal cells which depend on 
mitochondrial respiration to produce energy, majority of cancer cells use glycolysis instead, and 
this phenomenon is named “the Warburg effect” [66]. Although aerobic glycolysis is much less 
efficient in ATP production compared with oxidative phosphorylation, it provides a much larger 
number of intermediates for the de novo macromolecule biosynthesis of protein, lipids, and 
nucleic acids. On the other hand, cancer cells also have a much higher rate of glucose uptake to 
meet their energy needs [67]. More recently, other metabolic alterations in glutaminolysis, amino 
acid metabolism, lipid metabolism as well as other biosynthetic and bioenergetic pathways have 
also been found in cancer, and all of these metabolic reprogramming are thought to be required 
for anabolic growth of cancer cells [68]. 
Studies in the past decade have demonstrated that p53 can counteract the effects of 
metabolic alteration through regulating numerous metabolic targets, resulting in inhibition of 
aerobic glycolysis, up-regulation of mitochondrial oxidative phosphorylation, and promotion of 
fatty acid oxidation [69]. In addition, several metabolic targets also function to increase 
antioxidant defense and protect cells from ROS-induced DNA damage and malignant 
transformation. TP-p53 induced glycolysis and apoptosis regulator (TIGAR), an enzyme that 
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converts fructose-2,6-bisphosphate to fructose-6-phosphate, was identified to be a direct target of 
p53 [70]. This conversion shunts the glycolytic intermediates into pentose phosphate pathway for 
NADPH production and glutathione recycling, therefore reducing glycolytic rate and decreasing 
intracellular ROS [70]. Additionally, p53 inhibits glycolysis through transcriptionally repressing 
the expression of glucose transporters such as GLUT1, GLUT3, and GLUT4 [71].  Besides 
glycolysis, p53 also plays an important role in the regulation of mitochondria and oxidative 
phosphorylation. p53 has been indicated to induce the synthesis of cytochrome c oxidase 2 
(SCO2), a key regulator of the cytochrome C oxidase complex in the electron transport chain, 
which functions to increase mitochondrial respiration [72]. Glutaminase 2 (GLS2) is also a p53 
target that converts glutamine to glutamate, and functions to enhance TCA cycle and 
mitochondrial respiration through promoting the production of glutamate and α-ketoglutarate. 
[73, 74]. Additionally, expression of GLS2 protects the cells from oxidative stress-induce cell 
death by increasing the synthesis of reduced glutathione (GSH) and decreasing ROS levels [73, 
74].                
    Recent findings have also linked p53 to the regulation of lipid metabolism. Fatty acids (FAs) 
is a major group of lipids that constitute the cell membrane, and the regulation of FA metabolism 
is critical for maintaining energy balance [75]. In fact, to support anabolic growth, many cancer 
cells exhibit increased FA synthesis and decreased FA oxidation (FAO), both of which could be 
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counteracted by p53 through the regulation of several metabolic target genes. Upon glucose 
deprivation, activated p53 induces the expression of guanidinoacetate N-methltransferase 
(GAMT), which leads to increased FAO in both liver tissue and cultured cells [76]. Another p53 
target lipin1 (LPIN1), when induced upon nutrient starvation, could cooperate with peroxisome 
proliferator-activated receptor gamma coactivator 1α (PGC-1α) and peroxisome 
proliferator-activated receptor alpha (PPARα) to enhance FAO and inhibit FA synthesis through 
regulating the expression of genes involved in FA metabolism pathways [77, 78]. NAPDH, a 
cofactor that is produced from pentose phosphate pathway, is required for lipid synthesis. In fact, 
p53 has been indicated to inhibit the activity of glucose-6-phophate dehydrogenase (G6PD), a 
rate-limiting enzyme in the pentose phosphate pathway, and therefore, reduce NAPDH levels and 
lipid synthesis [79]. Furthermore, p53 inhibits lipogenesis through repressing the expression of 
sterol regulatory element-binding protein SREBP1c, a transcription factor that regulates 
lipogenesis [80].  
1.4.2 Ferroptosis 
    Our recent study has revealed that p53 can induce ferroptosis by suppressing the expression 
of SLC7A11, a component of the cystine/glutamate antiporter (system xc
-
) [81]. Ferroptosis is 
form of non-apoptotic, iron-dependent and programmed cell death that is known to be driven by 
membrane lipid peroxidation. Ferroptosis is morphologically distinct from apoptosis and 
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necroptosis, which is featured by the presence of shrunken mitochondria, increased mitochondria 
membrane density, and the absence of DNA fragmentation [81]. Erastin and RSL3 are the first 
two ferroptosis-inducing compounds that were discovered using small-molecule high-throughput 
screening [82, 83]. Cells treated with Erastin or RSL3 died in the absence of apoptosis markers 
[83]. Knockdown or pharmacological inhibition of RIPK1, a key component of necroptosis, did 
not rescue Erastin-induced cell death [84]. Moreover, iron chelators were found to inhibit 
RSL3-induced cell death, suggesting that cellular iron is required for this type of cell death [83]. 
Glutathione peroxidase 4 (GPX4) is a target protein for RSL3 that was recently identified to be a 
central regulator of ferroptosis. Using glutathione as a cofactor, GPX4 decreases cellular ROS 
levels and reduces lipid hydroperoxides on cellular membranes [85]. Knockout of Gpx4 led to 
accumulation of lipid ROS in mouse brain tissue and caused rapid motor neuron degeneration by 
ferroptosis [86, 87].  Conditional ablation of Gpx4 in mouse T cells also resulted in T cell 
ferroptosis and decreased immune response [88]. This suggests that ferroptosis plays an 
important role in development. System xc
-
 is another key regulator of ferroptosis, and it can by 
inhibited by Erastin. System xc
-
 is responsible for the uptake of cystine, which is a precursor for 
glutathione synthesis. Inhibition of System xc
-
 by Erastin depletes the intracellular cystine levels, 
and results in glutathione depletion and ferroptosis [84]. Our recently study revealed that through 
repressing the expression of SLC7A11, a component of  System xc
-
, p53inhibits cystine take 
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and sensitizes cells to ferroptosis upon ROS-induced stress [81]. Moreover, overexpression of 
SLC7A11 significantly abrogated the tumor growth suppression activity of p53
3KR
, indicating 
that p53-mediated ferroptosis is important for its tumor suppression functions [81].  
1.4.3 Autophagy 
    Autophagy is an intracellular degradation system that delivers long-lived proteins and 
damaged organelles for degradation and recycling in lysosomes. It functions to eliminate 
unwanted cellular components and protect cells from nutrient starvation. p53 has been revealed 
to both induce and inhibit autophagy, depending on its sub-cellular localization [89]. Nuclear 
p53 promotes autophagy through transcriptional activation of several target genes that stimulate 
autophagy. DRAM (damage-regulated autophagy modulator) is a direct target of p53 that 
functions as a lysosomal membrane protein to induce autophagy [90]. Although overexpression 
of DRAM alone induces minimal cell death, it is found to be essential for p53-mediated 
apoptosis [90]. Moreover, the expression of DRAM is frequently decreased in primary tumors 
accompanied by retention of wild-type p53, suggesting that DRAM-mediated autophagy may 
contribute to p53-mediated tumor suppression [90]. mTOR (mammalian target of rapamycin) is a 
sensor for cellular nutrients and energy levels, and inhibits autophagy as one of its downstream 
events . AMP-activated protein kinase (AMPK) and tuberous sclerosis complex (TSC1/2) are 
negative regulators of mTOR, when activated upon energy deprivation, would promote 
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autophagy through inhibition of mTOR [91]. In fact, p53 can transcriptionally activate both the 
β1 and β2 subunits of AMPK as well as TSC2, resulting in induction of autophagy [92]. In 
contrast to nuclear p53, cytoplasmic p53 seems to inhibit autophagy through 
transcription-independent mechanisms, although the exact molecular mechanism remains to be 
elucidated. Some studies have demonstrated that the inhibitory effect of autophagy is determined 
by the ratio of cytoplasmic p53 to nuclear p53 levels, with higher cytoplasmic p53 resulting in 
greater autophagic inhibition [28, 93]. 
1.5 Mechanism of p53-mediated tumor suppression 
    Since p53 functions as a tumor suppressor through regulating a wide variety of target genes 
involved in different functional areas, it is important to understand which functions of p53 
contribute to tumor suppression. The growth arrest, apoptosis, and senescence functions of p53 
have long been accepted as the major mechanism to suppress tumorigenesis. However, several 
recent studies have challenged this old view, indicating that the tumor suppressive function of 
p53 can be achieved in the absence of cell cycle arrest, apoptosis, and senescence.  
1.5.1 Growth arrest, apoptosis, and senescence are dispensable for p53-mediated tumor 
suppression 
    p21 single knock-out and Puma/Noxa double knock-out mice were first generated to 
evaluate the role of growth arrest and apoptosis in tumor suppression. However, neither of them 
18 
 
developed spontaneous tumor formation, possibly due to the compensation for each other 
between these two functions [52, 94, 95]. Surprisingly, later study also failed to observe any 
increased tendency of tumorigenesis in triple knock-out mice of p21, Puma, and Noxa [96]. 
Notably, mouse p53
3KR
, an acetylation deficient mutant of p53 on lysine residues K117, K161, 
and K162 (homologous to K120 and K164 in human p53), is defective in p53-dependent cell 
cycle arrest, senescence, and apoptotic responses [97]. However, unlike p53-null mice which 
develop early onset of thymic lymphomas within 6 months of age, all of the p53
3KR/3KR
 knock-in 
mice remain tumor free and healthy up to 16 months [97].  Similarly, another p53 knock-in 
mouse model containing two mutated residues in codon 25 and 26 at N-terminal transactivation 
domain (p53
25,26/25,26
) also showed intact tumor suppression although p53
25,26
 is compromised in 
its ability to activate the transcription of apoptotic and growth arrest targets [98]. These studies 
suggest that the growth arrest, apoptosis, and senescence functions of p53 are dispensable for it 
to suppress tumor formation, underscoring the potential significance of non-canonical functions 
of p53 in contributing to p53-mediated tumor suppression. Interestingly, p53
3KR/3KR
 mice retain 
the ability to regulate metabolism and induce ferroptosis through certain target genes, including 
TIGAR, GLS2, GLUT1/4, and SLC7A11, and these functions of p53 may play an important role 
in p53-mediated tumor suppression [81, 97].  
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1.5.2 Role of non-canonical functions of p53 in tumor suppression 
    Although p53 can regulate a variety of metabolic targets that function to counteract the 
metabolic alterations commonly observed in cancer cells, such as increased glycolysis, decreased 
mitochondria respiration and lipid oxidation, the link between metabolic reprogramming and 
tumorigenesis remains elusive. Studies have shown that p53 metabolic targets have both tumor 
suppressive and tumor promoting properties. Loss of GLS2, a p53 metabolic target in glutamine 
metabolism and ROS regulation, has been indicated to correlate with neoplastic transformation 
in human hepatocellular carcinomas [99]. In addition, low expression of SCO2, a p53-regulated 
target in mitochondria respiration, has been revealed to be associated with poor prognosis in 
human invasive breast cancers [100]. These results suggest that p53-mediated regulation of 
GLS2 and SCO2 may contribute to tumor suppression possibly by prevent metabolic 
transformation. In contrast, TIGAR, a bona fide p53 metabolic target that functions to inhibit 
glycolysis and increase antioxidant production, is demonstrated to have tumor-protective 
activities. Cheung et al. reported that TIGAR knockout mice displayed decreased tumor burden 
compared with TIGAR wild-type mice in an intestinal adenoma mouse model [101]. They 
revealed that Tigar expression increases GSH: GSSG ratio in intestinal tumor cells, thus 
preventing the accumulation of ROS [102]. Additionally, Tigar also up-regulates the synthesis of 
nucleotide and allow cancer cells to proliferate more efficiently [102]. In fact, the antioxidant 
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function of p53 seems to play a dual role in tumor formation and development. While decreasing 
the intracellular ROS level by p53 could protect normal cells from oxidative damage to DNA, 
and potentially prevent malignant transformation; it also could support the survival and growth 
of cancer cells by alleviating the toxicity from oxidative stresses. Further studies are required to 
dissect the role of p53-mediated metabolic regulation and antioxidant function in tumor initiation 
and progression.  
    Interestingly, recent discovery of the link between p53 and ferroptosis has shed light on the 
previously unanticipated tumor suppression mechanism of p53. Besides modulating ROS levels, 
p53 can also directly respond to ROS stress or accumulation through repressing the expression of 
SLC7A11, and result in inhibition of cystine uptake, increase of lipid peroxidation, and induction 
of ferroptosis. In fact, SLC7A11 is found to be overexpressed in many types of human cancers 
[81]. Jiang et al. also revealed that p53
3KR
, an acetylation-deficient p53 mutant that is defective 
in p53-mediated growth arrest, apoptosis, and senescence, retains the ability to repress SLC7A11 
expression and trigger ferroptosis in response to oxidative stress [81]. Although p53
3KR
 retains 
intact tumor suppression activity, reconstitution of robust SLC7A11 expression in p53
3KR
 cancer 
cells significantly abrogated its ability to suppress tumor formation in xenograft mouse models 
[81]. Moreover, a ferroptosis inhibitor (Ferrastatin-1) was demonstrated to reverse the 




 embryos, suggesting that p53-mediated ferroptosis 
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also contributes to embryonic development and the lethality associated with loss of Mdm2 [81]. 
Additionally, a recent study reported that the tumor-prone S47, an African-specific 
polymorphism of p53, is specifically impaired in its ability to transactivate a subset of target 
genes involved in ferroptotic responses, suggesting the potential relevance of ferroptosis to 
tumor suppression by p53 [103]. Together, these findings implicate that p53-mediated ferroptosis 
denote another critical layer of defense against tumorigenesis independently from cell cycle 
arrest, apoptosis, and senescence.  
    In fact, both DNA damage and intracellular ROS acquired from exogenous stress or 
endogenous cellular metabolism could promote tumor initiation and malignant transformation, it 
can also be detrimental in excess. The divergent effects of p53 in response to DNA damage and 
oxidative stresses suggest that p53 plays an intricate role in balancing cell survival and death to 
maintain cellular integrity and prevent tumor formation. In response to low levels of DNA 
damage and ROS, p53 promotes cell survival by inducing cell cycle arrest and alleviating ROS 
accumulation to repair both genotoxic and oxidative damage. While upon inappropriate levels of 
DNA damage and oxidative stress, p53 is activated to eliminate unsalvageable cancer cells 
through both apoptosis and ferroptosis. Notably, since ferroptosis is a fairly new field that was 
discovered recently, there is much yet to be uncovered regarding its molecular mechanism and 
unknown regulators. It is possible that additional components of the ferroptosis pathway involve 
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p53. Further studies are required to elucidate the regulation of ferroptosis by p53, and its role in 
p53-mediated tumor suppression. 
1.6 Summary 
    Although p53 has been extensively studied over the past three decades, a better 
understanding of the non-canonical functions of p53 and their roles in mediating tumor 
suppression are further required. The experiments in this study were designed to expand the 
scope of p53 unconventional functions (including metabolic regulation and ferroptosis) through 
novel targets identification, and to explore their contribution to p53 as a tumor suppressor. In this 
study, we identified PHGDH and SAT1 as two novel metabolic targets of p53 that are involved in 
p53-mediated apoptotic and ferroptotic responses, respectively. We also uncovered two novel 
acetylation sites that are pivotal for the regulation of metabolic target genes (including SAT1, 
SLC7A11, and TIGAR), and revealed that p53-mediated ferroptotic response via SAT1 and 
















Identification of Phosphoglycerate Dehydrogenase (PHGDH)  











2.1 Background and Rationale 
    Cancer cells are known to have altered metabolism. As described by Otto Warburg, the 
majority of tumor cells use aerobic glycolysis instead of mitochondrial respiration to produce 
energy and support cell growth and proliferation [104]. In addition, the metabolic 
reprogramming towards macromolecule biosynthesis, which is thought to sustain rapid cell 
growth, is also being recognized as a hallmark of cancer [68]. There is accumulating evidence 
indicating that p53 plays a critical role in modulating metabolism in human cancers [105]; 
however, the precise mechanisms by which the metabolic activities contribute to overall p53 
responses are not well understood [106-109].  
    Recently, the serine synthesis pathway (SSP) has been shown to be essential in certain 
human cancers and contributes to oncogenesis through diverting glycolytic flux and further 
promote biosynthesis [110, 111]. L-serine is an important precursor for macromolecule 
biosynthesis. It is an essential amino acid for protein synthesis, as well as synthesis of 
sphingolipids and phospholipids, which are important components of cellular membranes [112, 
113]. The serine synthesis pathway converts the glycolytic intermediate 3-phosphoglycerate into 
serine via a 3-step reaction involving three metabolic enzymes: phosphoglycerate dehydrogenase 
(PHGDH), phosphoserine aminotransferase 1 (PSAT1) and phosphate ester hydrolysis (PSPH) 
[114]. L-serine can then be converted into glycine by serine hydroxymethyltransferase (SHMT), 
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which results in the formation of one-carbon (1C) units that contribute to de novo synthesis of 
purines and pyridines [115].
 
Specifically, PHGDH catalyzes the first and rate-limiting step of 
SSP from 3-phosphoglycerate to phospho-hydroxypyruvate, and is potentially important during 
tumor development. The human PHGDH gene is located in a highly amplified region of 
chromosome 1p [110]. It is frequently amplified and over-expressed in 70% of the ER-negative 
breast cancers, 39% of melanoma, and cervical cancers [110, 111, 116, 117]. Depletion of 
PHGDH in PHGDH amplified cells leads to an impairment of cell proliferation and serine 
synthesis in both breast cancer and melanoma cell lines [110, 111, 118], suggesting that the 
repression of the serine synthesis pathway may have therapeutic roles toward suppressing certain 
types of cancers. 
 
    Cancer cells can acquire L-serine from both de novo synthesis and extracellular 
environment. Upon serine starvation, PHGDH and PSAT1 are significantly up-regulated, and 
thereby, increases conversion of 3-phosphoglycerate to serine [119]. Furthermore, serine 
starvation also leads to p53-dependent metabolic remodeling in cancer cells [119]. In this study, 
we further investigated the contribution of p53 to the regulation of serine metabolism. p53 is 
widely accepted as a tumor suppressor and responds to varieties of cellular stresses [120]. It 
mainly functions as a transcription factor to monitor signaling pathways through 
promoter-specific regulation of target genes involved in cell growth arrest, apoptosis and 
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senescence [121]. Recent studies have suggested that p53 can also regulate metabolic 
reprogramming through numerous target genes, which includes TIGAR, GLUT1/3/4, GLS2, 
PARK3, and so forth [70, 71, 73, 74, 105, 107, 122]. Therefore, further understanding of the 
regulation of serine metabolism pathway by p53 might be crucial for revealing its mechanisms in 
tumor suppression.  
    Although p53 is frequently mutated in human cancers, 80% of human melanomas retain 
wild-type p53 [109, 123]. Furthermore, PHGDH is frequently amplified and highly expressed in 
melanoma [111]. As such, we focused our study on the interaction between p53 and PHGDH in 
melanoma cell lines. Here, we find that PHGDH is a novel p53 repressing gene in the serine 
biosynthesis pathway. PHGDH expression is significantly down-regulated upon treatment of 
Nutlin-3, a p53 agonist that has been developed to suppress tumor growth through interrupting 
the interaction of p53 and its negative regulator Mdm2 [124]. Although Nutlin-3 only induces 
p53-mediated growth arrest, not apoptosis [125-127], in melanoma cell lines expressing 
wild-type p53, we observed that serine starvation further sensitizes cells to Nutlin-3-induced 






2.2 Materials and Methods 
Plasmids  
    pGIPZ shRNA against TP53 and pTRIPZ shRNA against PHGDH were purchased from 
Thermo Scientific. A control hairpin in the pGIPZ vector that targeted GFP (shGFP) was used. 
pBabe-puro-FLAG-PHGDH was generated by PCR-based subcloning.  
Cell culture and stable lines  
    All cells were cultured in 37°C incubator with 5% CO2. All medium used were 
supplemented with 10% fetal bovine serum (FBS), 100 units/mL penicillin and 100 μg/mL 
streptomycin (all Gibco). For serine starvation experiments, cells were washed with PBS twice 
and fed with serine and glycine free medium (consist of MEM (11095, Gibco) supplemented 
with additional 1× MEM vitamins (11120, Gibco), 10% dialyzed-FBS (26400, Gibco) and 
additional D-glucose to 25mM (25-037-Cl, Cellgro)). For control medium, serine and glycine 
(Sigma) were added back to a final concentration of 0.4mM. According to Maddocks et al., 
serine is the major factor in serine and glycine starvation, therefore all starvation experiments 
were described as serine starvation [119]. To generate A375 cell line with stable knock-down of 
p53, HEK293T cells were transfected with pGIPZ shRNA vectors against TP53 and lenti-viral 
packaging vectors, and lenti-viruses produced from 293T were used to infect A375 cells. 
Selection under 1 μg/mL puromycin was carried out two days after infection. A375-PHGDH 
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stable cell line and A375 inducible knock-down of PHGDH cell line (A375-shPHGDH) were 
generated by similar procedure with pBabe-puro-FLAG-PHGDH and pTRIPZ-shPHGDH vector. 
To induce knock-down of PHGDH, 5 μg/mL of doxycycline (Sigma) were added to culture media.   
siRNA-mediated ablation of ATF4  
    Knock-down of ATF4 was performed by transfection of A375-shPHGDH cells with siRNA 
duplex oligoset (On-Target-Plus Smartpool L-00512500, Dharmacon) using Lipofectamine 
RNAiMAX (13778030, Invitrogen) according to manufacturer’s protocol. Control siRNA 
(On-Target-Plus siControl nontargeting pool D00181010, Dharmacon) was also used for 
transfection.  
Western blotting and antibodies 
    Cell lysates were prepared in Flag lysis buffer with fresh protease inhibitor cocktail. Protein 
extracts were analyzed by western blotting according to standard protocols using primary 
antibodies specific for PHGDH (HPA021241, Sigma), p53 (human: DO-1, Santa Cruz), Mdm2 
(Ab5, Millipore), Tigar (E-2, Santa Cruz), p21 (SX118, Santa Cruz), Puma (H-136, Santa Cruz), 
Cleaved-caspase3 (Asp175, Cell Signaling Technologies), ATF4 (sc-200, Santa Cruz) and 
β-Actin (A3853, Sigma-Aldrich). HRP-conjugated anti-mouse and anti-rabbit secondary 
antibodies (GE Healthcare) were used and signals were detected on autoradiographic films with 




RNA extraction and qRT-PCR 
     Total RNA was extracted using TRIzol Reagent (Life Technologies) according to the 
manufacturer’s protocol. cDNA was synthesized from total RNA using M-MulV Reverse 
Transcriptase kit (NEB). PCR analysis was performed using Applied Biosystems 7500 Fast 
System. For the qRT-PCR analysis of human transcripts the following primers were used: 
PHGDH forward 5’-ATCTCTCACGGGGGTTGTG-3’,  
PHGDH reverse 5’-AGGCTCGCATCAGTGTCC-3’,  
ATF4 forward 5’-GGTCAGTCCCTCCAACAACA-3’,  
ATF4 reverse 5’-CTATACCCAACAGGGCATCC-3’,  
PUMA forward 5’-GGTCCTCAGCCCTCGCTCTC-3’,  
PUMA reverse 5’-CTTGTCTCCGCCGCTCGTAC-3’, 
NOXA forward 5’-CGTGTGTAGTTGGCATCTCCG-3’,  
NOXA reverse 5’-GACGCGAGCTGAACACGAAC-3’,  
BAX forward 5’-TTCTGACGGCAACTTCAACTGG-3’,  
BAX reverse 5’-CCCGGAGGAAGTCCAATGTC-3’,  
GAPDH forward 5’-ATCAATGGAAATCCCATCACCA-3’,  
GAPDH reverse 5’-GACTCCACGACGTACTCAGCG-3’.  
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Chromatin immunoprecipitation assay (ChIP)  
    ChIP assays were performed in transfected H1299 cells or A375 cells as previously 
described [128]. Primers used for p53 ChIP assay are:  
PHGDH forward 5'-TGAGAATATGCGGTGTTTGG-3',  
PHGDH reverse 5'-GGGTAAATGTGCAAGGCACT-3',  
TIGAR forward 5'-CGGCAGGTCTTAGATAGCTT-3',  
TIGAR reverse 5'- GGCAGCCGGCATCAAAAACA-3’. 
Electrophoretic mobility shift assay (EMSA) 
    Purified Flag-p53 protein was obtained from transfected H1299 cells. The 234-bp DNA 
probe containing p53 responsive elements was PCR-amplified from PHGDH promoter using 
PHGDH ChIP primers, labeled by T4 kinase (NEB, M0201S) and purified using the Bio-Spin 30 
columns (Bio-Rad). The protein-DNA binding reactions were performed as previously described 
[128]. In supershift assays, 100 ng pAb421 (Millipore) antibody were added to the reactions. 
Cell death count, drugs and inhibitors  
    Cells were trypsinized, collected and stained with trypan blue, followed by counting with a 
hemocymeter using standard protocol. Cells stained blue under the microscope were considered 
as dead cells. Nutlin-3 (Sigma) was used in experiments at a concentration of 10 µM, except 
otherwise indicated. DNA-damaging agent Doxorubicin (Dox, Sigma) was used at 0.2 μg/ml. 
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Specific cell death inhibitors were used in the experiments with indicated concentrations as listed: 
Z-VAD-fmk (caspase 3 inhibitor, Sigma), 10 µg/mL; 3-MA (autophagy inhibitor, Sigma), 2mM; 
Necrostatin-1 (necroptosis inhibitor, Sigma), 10 µg/mL; and Ferrostatin-1 (Ferroptosis inhibitor, 
Xcess Biosciences), 2 µM.  
Metabolite measurements  
    To measure steady-state metabolite levels, pre-chilled (on dry ice) 80% methanol was added 
onto cells in 10-cm culture dishes followed by incubation on dry ice for 15 min. Cells were then 
collected by scraping, and cellular metabolite was extracted by collecting the supernatant 
following centrifugation at 4,000 r.p.m for 10 min (4°C). The supernatant was then dried down 
using lyophilizer (Labconco) and stored at -80°C before subjected for LC-MS/MS based 
metabolite analysis at the Beth Israel Deaconess Medical Center Mass Spectrometry Core 
Facility as previously described [129].  Briefly, samples were suspended in HPLC grade water 
and analyzed using a 5500 QTRAP hybrid triple quadrupole mass spectrometer (AB/SCIEX) 
coupled to a Prominence UFLC HPLC system (Shimadzu) via selected reaction monitoring of a 
total of 254 endogenous water soluble metabolites using positive and negative polarity switching. 
Peak areas from the total ion current for each metabolite were integrated using MultiQuant v2.0 
software (AB/SCIEX). Three biological triplicates were analyzed for each treatment. In addition, 
two parallel dishes of cells were collected and measured for protein concentration using Bradford 
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assay (Bio-Rad). Subsequent metabolite measurements were normalized to total protein amount. 
2.3 Results and Discussion 
2.3.1 Nutlin-3 induces p53-mediated repression of PHGDH  
To evaluate the regulation of PHGDH by endogenous p53, we analyzed human melanoma 
cell lines containing wild-type p53 or mutant p53. Wild-type p53 cell lines (A375, Colo-829 and 
WM26-64) and mutant p53 cell lines (Colo-800 and Sk-mel28) were treated with Nutlin-3, a 
non-genotoxic drug that activates p53 by interrupting Mdm2-p53 interaction. Total cell lysates 
were then harvested and subjected to western blot analysis, and mRNA was extracted for 
quantitative real-time PCR (qRT-PCR). As expected, in p53-wildtype cell lines, the protein levels 
of p53, as well as its transcriptional targets Mdm2 and p21, were increased in response to 
Nutlin-3 treatment (Figure 2.1A). Notably, a significant decrease in both PHGDH protein and 
mRNA levels were also observed (Figure 2.1). However, we did not observe a change in 
PHGDH expression levels in p53-mutant melanoma cell lines after the same treatment (Figure 
2.1). To further determine p53 dependent regulation on PHGDH expression, we compared A375 
cells with p53-depletion to those without. Cells that underwent mock depletion and treated with 
Nutlin-3 showed a time-dependent reduction of both PHGDH protein and mRNA levels (Figure 
2.2). In contrast, the expression of PHGDH in p53-depleted cells remained unchanged after 
Nutlin-3 treatment (Figure 2.2). Together, these results indicate that PHGDH is transcriptionally 
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Figure 2.1. Nutlin-3 induces p53-mediated repression of PHGDH. (A) Western blot analysis 
of the protein levels of PHGDH, p53, Mdm2, p21 and Actin in indicated melanoma cell lines 
(A375, Colo-829 and WM26-64: p53 wild-type; Colo-800 and Sk-mel28: p53 mutant) without (-) 
or with (+) Nutlin-3 treatment (10μM) for 2 days. (B) The mRNA expression levels of PHGDH 
in the indicated melanoma cell lines treated with Nutlin-3 (10μM) were measured using 
qRT-PCR (bar graph). All mRNA expression levels were normalized with GAPDH. Error bars in 









Figure 2.2. Nutlin-3-induced repression of PHGDH is p53-dependent. (A) A375-shGFP and 
A375-shp53 stable knock-down cell lines were treated with Nutlin-3 (10μM) for the indicated 
times and total protein lysates were subjected to western analysis for the expression of PHGDH, 
p53, p21 and Actin. (B) qRT-PCR analysis of PHGDH mRNA levels in A375-shGFP and 
A375-shp53 cell lines treated with Nutlin-3 (10μM). All mRNA expression levels were 




2.3.2 DNA damage down-regulates PHGDH protein and mRNA levels in a p53-dependent 
manner 
To further confirm that PHGDH is a p53-repressing target, we examined PHGDH 
expression in response to DNA damage. As expected, DNA-damaging agent Doxorubicin (Dox) 
treatment induced activation of p53 (demonstrated by up-regulation of its downstream targets, 
p21) in p53-wildtype cell lines, but not in p53-mutant cell lines (Figure 2.3A). Notably, in all 
three p53-wildtype melanoma cell lines, the levels of PHGDH protein and mRNA were 
decreased upon Doxorubicin treatment (Figure 2.3). In contrast, PHGDH expression remained 
unchanged in p53-mutant melanoma cell lines, despite undergoing the same treatment (Figure 
2.3). Similarly, A375 cells that underwent mock depletion and treated with Doxorubicin showed 
a time-dependent reduction of both PHGDH protein and mRNA levels. However, the expression 
of PHGDH was not affected upon the same treatment in p53-depleted cells (Figure 2.4). These 
data collectively suggest that the expression of PHGDH is transcriptionally repressed by p53, 











Figure 2.3. DNA damage down-regulates PHGDH protein and mRNA levels in a 
p53-dependent manner. (A) Expression of endogenous PHGDH, p53, p21 and Actin in the 
indicated melanoma cell lines without (-) or with (+) DNA-damaging agent Doxorubicin 
treatment (0.2μg/mL). (B) qRT-PCR analysis of PHGDH mRNA levels in the indicated 
melanoma cell lines treated with Doxorubicin (Dox, 0.2μg/mL). All mRNA expression levels 








Figure 2.4. DNA damage-induced down-regulation of PHGDH is p53-dependent. (A) 
A375-shGFP and A375-shp53 stable knock-down cell lines were treated with Doxorubicin 
(0.2μg/mL) for the indicated times and total protein lysates were analyzed by western blotting for 
the expression of PHGDH, p53, p21 and Actin. (B) qRT-PCR analysis of PHGDH mRNA levels 
in A375-shGFP and A375-shp53 cell lines treated with Doxorubicin (0.2μg/mL) for indicated 
times. All mRNA expression levels were normalized with GAPDH. Error bars represent s.d. 




2.3.3 PHGDH promoter contains one p53 binding site 
As a transcription factor, p53 binds to its responsive elements (REs) in its target genes and 
regulates gene transcription in response to various stresses. As shown in Figure 2.5A, we found a 
consensus binding sequence in promoter region of the PHGDH gene that matches with p53 
binding site sequence [130]. To verify that p53 binds to its responsive element in the promoter 
region of the PHGDH gene, chromatin immunoprecipitation (ChIP) assays were performed. 
H1299 p53-null cells were transfected with p53 expression vector, cross-linked with 
formaldehyde, and p53-bound DNA were immunoprecipitated via anti-p53 antibody (α-p53). 
Resulting DNA fragments were amplified using primers flanking the predicted p53 binding site 
in the PHGDH promoter. In this assay, we observed enrichment of PHGDH and TIGAR 
promoter sequences in the presence of p53 (Figure 2.5B). Furthermore, binding of p53 at the 
PHGDH promoter was significantly enriched in A375 cells treated with either Nutlin-3 or 
Doxorubicin (Figure 2.6A). These results demonstrate that p53 interacts with the p53 responsive 
element in the PHGDH promoter in vivo.  
We next performed electrophoretic mobility shift assay (EMSA) to determine whether p53 
directly binds to PHGDH promoter in vitro. Notably, a p53/DNA complex was identified upon 
incubation of radiolabeled oligonucleotide probes containing the responsive element with 
purified full-length human p53 protein (Figure 2.6B). Moreover, the p53/DNA complex was 
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enhanced and super-shifted in the presence of anti-p53 antibody (ab421) (Figure 2.6B). 
Furthermore, binding of p53 to the radiolabeled fragments was diminished and out-competed by 
the addition of unlabeled probes (Figure 2.6B). Together, these results indicate that the PHGDH 
gene is a transcriptional target of p53 and that the consensus p53 binding site on the PHGDH 



















Figure 2.5. PHGDH promoter contains one p53 binding site. (A) Schematic representation of 
the promoter region in human PHGDH gene. The p53 binding site upstream of the first exon is 
indicated and compared with consensus p53 responsive element (p53 RE). Pu, purine; Py, 
pyramidine; N, any nucleotide. (B) ChIP-semi-quantitative analysis of p53 enrichment at the 
promoter regions of PHGDH and TIGAR in H1299 cells transfected with empty or p53 vector for 
24 hours. Cross-linked protein/DNA complex was immunoprecipitated using full-length anti-p53 









Figure 2.6. p53 binds to PHGDH promoter both in vitro and in vivo. (A) A375 cells were 
treated with vehicle, Nutlin-3 (10μM) or Doxorubicin (0.2μg/mL) for 24 hours, and ChIP assays 
for determining the enrichment of p53 on PHGDH and TIGAR promoters were carried out using 
anti-p53 antibody (α-p53) or control rabbit IgG. GAPDH was used as a negative control. (B) 
EMSA showing the binding of p53 on 
32
P-labeled oligonucleotides containing the p53-binding 
site in the human PHGDH promoter region. The DNA binding activity of purified p53 protein 
was enhanced with C-terminal p53 antibody pAb421 (α-p53). The binding specificity was 
verified using an excess of non-radiolabeled wild-type probes (competition). 
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2.3.4 Serine starvation promotes Nutlin-3-induced cell death through repression of PHGDH 
As a non-essential amino acid, serine can be acquired through de novo serine synthesis, as 
well as from exogenous nutrient source. Since serine is an important building block for 
biosynthesis and contributes to cancer cell growth, our findings that PHGDH is a p53 target 
suggest that PHGDH may mediate p53 function in controlling cell fate upon serine starvation. 
Previous studies have shown that treatment of Nutlin-3 on melanoma cell lines expressing 
wild-type p53 only induces p53-mediated cell cycle arrest but not apoptosis [125-127]. As 
expected, A375 cells (p53-wildtype) treated with Nutlin-3 only showed significant growth arrest 
with modest increase in cell death (Figure 2.7). Surprisingly, although serine starvation alone did 
not induce obvious growth arrest nor cell death, combination of serine starvation and Nutlin-3 
treatment induced significant cell death in A375 cells (Figure 2.7). Notably, Puma, a major p53 
up-regulated apoptosis modulator, was further activated upon combination treatments as 
compared to Nutlin-3 treatment alone, while p53 levels were the same in these two conditions, 
indicating that serine deprivation may lead to p53-independent Puma activation (Figure 2.8A). 
To ascertain whether the cell death is dependent on p53, p53-depleted A375 cells and p53-mutant 
melanoma cell lines (Colo-800 and Sk-mel28) were treated with Nutlin-3 and/or serine starvation. 
Notably, Nutlin-3 did not induce growth arrest nor cell death upon serine starvation in these cell 






Figure 2.7. Serine starvation sensitizes Nutlin-3 to induce cell. (A) Representative 
phase-contrast images of A375 cells treated with Nutlin-3 (10μM) with the presence (Complete 
medium) or absence (Ser. Starv.) of serine in culture medium. (B) The percentages of cell death 










Figure 2.8. Nutlin-induced cell death upon serine starvation is p53-dependent. (A) Western 
blot analysis of expression levels of PHGDH, p53, Puma, Tigar and Actin in A375 cells treated 
with Nutlin-3 (10μM) with the presence or absence of serine. (B) The percentages of cell death 
in A375-shGFP and A375-shp53 stable knock-down cells treated with Nutlin-3 (10μM) in the 
presence or absence of serine. (C) The percentages of cell death in p53 mutant cell lines 









To further explore the effect on cell fate by p53-mediated repression of PHGDH, we 
generated a PHGDH over-expression stable cell line in A375 (A375-PHGDH). As shown in 
Figure 2.9A, while the expression of PHGDH was decreased upon Nutlin-3 treatment in A375 
cells, it remained unchanged and over-expressed in A375-PHGDH cells after the same treatment, 
indicating that the high expression level of exogenous PHGDH negates the repressive effect of 
p53 on endogenous PHGDH expression. As a result, serine starvation failed to sensitize 
A375-PHGDH cells to Nutlin-3-induced cell death (Figure 2.9B), indicating that the cell death 
induced by the combination of Nutlin-3 and serine starvation is mediated through repression of 
PHGDH by p53. Together, our results indicate that the function of p53 in repressing PHGDH 

















Figure 2.9. Serine starvation sensitizes Nutlin-3 to induce cell death through repression of 
PHGDH. (A) A375 and A375-PHGDH cell lines were treated with the indicated concentrations 
of Nutlin-3 for 48 hours, and the expression levels of PHGDH, p53, Tigar, p21 and Actin were 
measured by western blotting. (B) The percentages of cell death in A375 and A375-PHGDH cell 
lines treated with Nutlin-3 (10μM) under normal or serine starvation condition. All error bars 






2.3.5 Mechanistic insights into the apoptotic response regulated by PHGDH upon serine 
starvation 
    To understand the mechanisms of how serine starvation sensitizes cells to cell death upon 
Nutlin-3 treatment in p53-wildtype melanoma cell lines, we investigated whether PHGDH 
depletion is sufficient to induce cell death upon serine removal. As such, a doxycycline-inducible 
shRNA cell line in A375 targeting PHGDH (Tet-on A375-shPHGDH) was generated. As shown 
in Figure 2.10A, PHGDH expression was efficiently depleted upon addition of doxycycline. 
Cells that underwent mock depletion or PHGDH depletion were then incubated in control 
medium or serine starvation medium for an additional 48 hours. Notably, PHGDH depletion in 
A375 cells induced significant cell death upon serine starvation, while PHGDH depletion or 
serine starvation alone did not affect cell survival (Figure 2.10B and 2.11A). Interestingly, the 
cell death induced by PHGDH depletion and serine starvation was completely rescued by 
caspase-3 inhibitor Z-VAD-fmk, but not inhibitors of other forms of cell death, including 
autophagy (3-MA), necroptosis (Necrostatin-1) and ferroptosis (Ferrostatin-1) (Figure 2.10B and 
2.11A). Western blot analysis also showed elevated levels of cleaved-caspase-3 and Puma in 
cells that were undergoing cell death (Figure 2.11B). These results indicate that the synergistic 







Figure 2.10. PHGDH knock-down induces apoptosis upon serine starvation. (A) qRT-PCR 
analysis of PHGDH mRNA levels in Tet-on A375-shPHGDH stable cell line after adding 
doxycycline (Doxy, 5μg/mL) for 3 days. Western blot analysis also showing the expression 
levels of PHGDH and Actin in Tet-on A375-shPHGDH cells after adding doxycycline. (B) 
Representative phase-contrast images of A375 cells expressing doxycycline-inducible shRNA 
against PHGDH, with or without serine starvation (Ser Starv.) for 48 hours. Images also showing 
A375-shPHGDH cells under serine starvation condition with the addition of cell death inhibitors 
(Z-VAD-fmk, caspase-3 inhibitor, 10μg/mL; 3-MA, autophagy inhibitor, 2mM; Necrostatin-1, 







Figure 2.11. PHGDH knock-down induces apoptosis upon serine starvation (continued). (A) 
The percentages of cell death for all experiments shown in Figure 2.10B were measured by 
trypan blue exclusion assay. (B) A375 shPHGDH cells and A375 cells were incubated in serine 
starvation medium for the indicated times and total protein lysates were subjected to western 






Although the link between apoptotic pathways and amino acid starvation is not fully 
understood, recent studies suggested that activation transcription factor 4 (ATF4) plays an 
important role in regulating amino acid metabolism and tumor cell death under stress conditions 
[131]. Qing et al. found that glutamine starvation induces apoptosis through ATF4-dependent, 
but p53-indepdent, Puma and Noxa induction in MYC-transformed cells [131]. In our study, 
metabolite analysis showed that steady-state serine levels were markedly decreased in 
PHGDH-depleted A375 cells upon serine starvation (Figure 2.12A). Meanwhile, a significant 
up-regulation of ATF4, Puma and Noxa levels, and a slight induction of apoptosis regulator Bax 
were observed in A375 cells undergoing apoptosis (Figure 2.12B). However, no p53 activation 
was present in this condition (Figure 2.11B). To further prove that PHGDH knock-down induced 
apoptosis upon serine starvation is indeed dependent on ATF4, PHGDH-depleted A375 cells 
were transfected with control siRNA or ATF4 siRNA, and then incubated in control medium or 
serine-free medium. While ATF4 expression was significantly up-regulated upon serine 
starvation in PHGDH knock-down A375 cells, its expression was completely ablated upon ATF4 
knock-down (Figure 2.13A). Notably, activation of Puma was abolished and lower levels of 
cleaved-caspase-3 were observed upon ATF4 knock-down, while no p53 activation was present 
under any conditions (Figure 2.13A). Furthermore, ATF4 siRNA significantly reduced serine 
starvation-induced cell death in PHGDH-depleted A375 cells (Figure 2.13B). These results 
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collectively indicate that the apoptosis induced by PHGDH depletion upon serine starvation is 




Figure 2.12. PHGDH knock-down induced depletion of cellular L-serine and activation of 
ATF4 upon serine starvation. (A) Metabolite analysis showing the intracellular steady levels of 
serine in A375-shPHGDH cells cultured in complete medium or serine starvation medium (Ser 
Starv.). (B) qRT-PCR analysis of mRNA levels of ATF4, Puma, Noxa and Bax in 






Figure 2.13. ATF4 mediates PHGDH knock-down induced apoptosis upon serine starvation. 
(A) A375 shPHGDH cells were first transfected with control siRNA or ATF4 siRNA for 24 hours, 
and then incubated in complete medium or serine starvation medium for up to 48 hours. Total 
cell lysates were harvested and subjected to western analysis for the expression of PHGDH, 
ATF4, Puma, Cleaved-caspase3 and p53. Vinculin was used as loading control. (B) 
Representative phase-contrast images of A375-shPHGDH cells transfected with control or ATF4 
siRNA in the presence or absence of serine at 48 hours. (C) The percentages of cell death were 













Identification of Spermidine/spermine N
1
-acetyltransferase 1 (SAT1)  










3.1 Background and Rationale 
    Recently, the identification of a novel p53 target SLC7A11 in cystine uptake has highlighted 
the importance of ferroptosis in p53-mediated tumor suppression [81]. Ferroptosis is an 
iron-dependent non-apoptotic cell death that can be triggered by inhibition of cystine uptake, 
decrease of glutathione (GSH) synthesis, and subsequent accumulation of lipid ROS [84]. Jiang 
et al. reported that in response to inappropriate levels of ROS, p53 promotes ferroptosis through 
down-regulation of SLC7A11, a component of the cystine/glutamate antiporter (system xc
-
), and 
therefore, provides another layer of defense against cellular injury and tumorigenesis [81]. 
Nonetheless, it is possible that additional p53 targets may also contribute to this novel p53 
response. Therefore, further investigation is required to demonstrate the role of other metabolic 
targets of p53 in regulating ferroptotic cell death. In this section, we used RNA sequencing 
technique to search for novel metabolic targets of p53 in a p53 wild-type melanoma cell line 
A375 treated with Nutlin, a non-genotoxic drug that is commonly used to activate p53 through 
inhibiting its negative regulator MDM2 [132]. Our analysis identified a novel gene SAT1 in the 
polyamine metabolism pathway that is highly induced by p53. 
    The polyamines are amino-acid-derived polycationic alkylamines that are essential for the 
growth and survival of eukaryotic cells [133]. They consist of putrescine, spermidine and 
spermine, and their levels are tightly controlled and regulated by enzymes involving polyamine 
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biosynthesis, catabolism and transport [134]. Notably, Scuoppo et al. reported that deletion of 
genes in polyamine-hypusine axis results in increased tumor formation in a mouse lymphoma 
model, implicating the role of polyamine metabolism in modulating tumorigenesis [135]. 
Furthermore, polyamine metabolism is found to be frequently dysregulated in cancers, thus 
making it an attractive target for therapeutic intervention [134, 136]. Spermidine/spermine 
N
1
-acetyltransferase 1 (SAT1) is the rate-limiting enzyme controlling the first intracellular 
pathway of polyamine catabolism. As shown in Figure 3.1, SAT1 catalyses the acetylation of 




-acetylspermine, which are then 
either exported from the cells, or converted back to putrescine or spermidine by 
N
1
-acetylpolyamine oxidase (PAO) [137]. Therefore, overexpression of SAT1 leads to an overall 










(DENSpm), a polyamine analogue that is known to induce SAT1, has been applied in several 
clinical trials in patients with advanced malignancies [139-142]. Nonetheless, it remains largely 
unknown whether SAT1 has a role in tumor suppression, and the molecular mechanism of 
polyamine metabolism in modulating tumorigenesis is not well understood either.  
    In this study, we identified SAT1 as a novel p53 metabolic target gene that can be induced 
by both endogenous and exogenous p53. Expression of SAT1 in xenograft cells significantly 
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impaired tumor growth, indicating that it acts as a tumor suppressor in vivo. Surprisingly, we also 
discovered that SAT1 is involved in regulating p53-mediated ROS response and ferroptosis. 
These findings further broadened our understanding of the complex regulation of ferroptotic cell 






Figure 3.1. Polymaine metabolism pathway. SAT1, spermine/spermidine N
1
-acetyltransferase 
1; ODC, ornithine decarboxylase; PAO, N
1
-acetylpolyamine oxidase; SpdS, spermidine synthase; 






3.2 Materials and Methods 
Cell culture and stable lines 
    All cells were cultured in 37°C incubator with 5% CO2. All media used for cancer cell lines 
were supplemented with 10% fetal bovine serum (FBS), 100 units per ml penicillin and 100 
μg/ml streptomycin (all Gibco). MEFs were generated from day 13.5 embryos according to 
standard procedures. FBS used for MEFs was heat-inactivated and supplemented with 1% 
non-essential amino acids. p53 inducible stable line was generated in H1299 cell line as 
previously described [81]. To induce the expression of p53, 0.5 μg/mL of tetracycline was added 
into culture medium. To generate SAT1 inducible stable line, human SAT1 complementary DNA 
was cloned into Tet-on pTRIPZ inducible expression vector (Thermo Open Biosystems) 
followed by transfection using Lipofectamine 2000 (Invitrogen), selection and maintenance with 
puromycin (1 μg/mL) in DMEM medium containing 10% tetracycline-free FBS. 0.5 μg/ml of 
doxycycline was used to induce the expression of SAT1. p53 CRISPR-cas9 knockout U2OS cell 
lines were generated by transfection of p53 double nickase plasmid (sc-416469-NIC, Santa Cruz) 
followed by selection with puromycin (1 μg/mL). Similarly, SAT1 CRISPR-cas9 knockout U2OS 
cell lines were generated by transfection of pGL3-U6-sgRNA-PGK-puromycin vectors 
containing guide RNAs targeting exon 4, and pST1374-Cas9 vector. Guide RNA sequences 
targeting SAT1 gene are 5’- GTCATAGGTAAAATAGTACATGG -‘3 and 5’- 
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TGGCAAGTTATTGTATCTTGAGG -3’. Single colonies with p53 or SAT1 knockout were 
selected and used for experiments. Knock-down of SAT1 was performed by transfection of MEFs 
with siRNA duplex oligoset (On-Target-Plus Smartpool L05579601, Dharmacon) two times with 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol.   
Western blotting and antibodies 
    Cell lysates were prepared in Flag lysis buffer with fresh protease inhibitor cocktail. Protein 
extracts were analyzed by western blotting according to standard protocols using primary 
antibodies specific for p53 (human: DO-1, Santa Cruz), MDM2 (Ab5, Millipore), TIGAR (E-2, 
Santa Cruz), PUMA (H-136, Santa Cruz), p21 (SX118, Santa Cruz), Actin (A3853, 
Sigma-Aldrich), SAT1 (H-7, Santa Cruz), Cleaved-caspase3 (Asp175, Cell Signaling 
Technologies), Cleaved-PARP(9542S, Cell Signaling Technologies) and GPX4 (ab125066, 
Abcam). HRP-conjugated anti-mouse and anti-rabbit secondary antibodies (GE Healthcare) were 
used and signals were detected on autoradiographic films with Pierce ECL western blotting 
detection system or SuperSignal West Dura reagents (Thermo scientific).  
RNA extraction and qRT-PCR 
    Total RNA was extracted using TRIzol Reagent (Life Technologies) according to 
manufacturer’s protocol. cDNA was synthesized from total RNA using M-MulV Reverse 
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Transcriptase kit (NEB). PCR analysis was performed using Applied Biosystems 7500 Fast 
System. For the qRT-PCR analysis of human transcripts the following primers were used:  
SAT1 forward 5’ -CCGTGGATTGGCAAGTTATT- 3’,  
SAT1 reverse 5’ -TCCAACCCTCTTCACTGGAC-3’,  
PTGS2 forward 5’ -CTTCACGCATCAGTTTTTCAAG- 3’,  
PTGS2 reverse 5’ -TCACCGTAAATATGATTTAAGTCCAC- 3’,  
ALOX15 forward 5’ -AGCCTGATGGGAAACTCTTG- 3’,  
ALOX15 reverse 5’ -AGGTGGTGGGGATCCTGT -3’,  
ALOX5 forward 5’ -CCTCAGGCTTCCCCAAGT- 3’,  
ALOX5 reverse 5’ -GAAGATCACCACGGTCAGGT- 3’,  
ALOX12 forward 5’ -GCTCCTGGAACTGCCTAGAA- 3’,  
ALOX12 reverse 5’ -TCATCATCCTGCCAGCACT- 3’,  
GPX4 forward 5’ -TTCCCGTGTAACCAGTTCG- 3’,  
GPX4 reverse 5’ -CGGCGAACTCTTTGATCTCT- 3’,  
GAPDH forward 5’ -ATCAATGGAAATCCCATCACCA- 3’,  
GAPDH reverse 5’ -GACTCCACGACGTACTCAGCG- 3’.  
For the qRT-PCR analysis of mouse transcripts the following primers were used:  
SAT1 forward 5’ -GGCTAAATTTAAGATCCGTCCA- 3’,  
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SAT1 reverse 5’ -CATGTATTCATATTTAGCCAGTTCCTT- 3’. 
Chromatin immunoprecipitation assay (ChIP) 
    ChIP assays were performed as previously described in H1299 cells transfected with empty 
vector or pCIN4-p53 [143]. Primers used for ChIP quantitative-PCR are:  
SAT RE1 forward 5'- CAGTAGGGTTTCCGCCAAG -3',  
SAT1 RE1 reverse 5’- AACCCGGAGGACAAAAGTG -3’,  
SAT RE2 forward 5'- TCCTGAGTTTGCTTCCCACT -3',  
SAT1 RE2 reverse 5’- GGTGTGTCCCCCAGTAACAT -3’,  
SAT RE3 forward 5'- CACTGATTCTCAACTGCCAAA -3',  
SAT1 RE3 reverse 5’- CAGAAGCAGAGGAGGAAAAGG -3’,  
SAT RE4 forward 5'- CAAAAGACCACCCCTCACAT -3',  
SAT1 RE4 reverse 5’- CCTAGGGCAGGAAGGGTAAC -3’,  
TIGAR forward 5’- CGGCAGGTCTTAGATAGCTT -3’,  
TIGAR reverse 5’- GGCAGCCGGCATCAAAAACA -3’. 
Cell death count, drugs and inhibitors 
    Cells were trypsinized, collected and stained with trypan blue, followed by counting with a 
hemocymeter using standard protocol. Cells stained blue under the microscope were considered 
as dead cells. Nutlin (Sigma) was used in experiments at a concentration of 10µM. 
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DNA-damaging agent doxorubicin (Dox, Sigma) was used at 0.2 μg/mL. ROS generator tert-butyl 
hydroperoxide (TBH, Sigma) was used at a concentration of 60µM in H1299 cells, 350µM in 
U2OS cells and 150µM in MEFs respectively. Specific cell death inhibitors were used in the 
experiments with indicated concentrations as listed: Z-VAD-fmk (caspase 3 inhibitor, Sigma), 10 
µg/mL; Necrostatin-1 (necroptosis inhibitor, Sigma), 10 µg/mL; Ferrostatin-1 (Ferroptosis 
inhibitor, Xcess Biosciences), 2 µM; 3-MA (autophagy inhibitor, Sigma), 2mM; and PD146176 
(ALOX15 inhibitor, Sigma), 1 µM. 
Analysis of reactive oxygen species (ROS) production 




) once, and then incubated with 
PBS containing 2µM C11-BODIPY(581/591) or 25µM H2DCFDA (both from Invitrogen) at 37°C 
for 30min in tissue culture incubator. Cells were then washed, harvested by trypsinization and 
resuspended in 500µl fresh PBS. ROS levels were analyzed using a Becton Dickinson 
FACScalibur machine through FL1 channel, and data were analyzed using CellQuest. 10,000 
cells were analyzed in each sample.  
Mouse xenograft 
    SAT1 Tet-on stable H1299 cells were trypsinized, counted and then 1.5 × 10
6
 cells were 
mixed with Matrigel (BD Biosciences) at 1:1 ratio (volume) and injected subcutaneously into 
nude mice (NU/NU, Charles River). Mice were fed either with control food or food containing 
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doxycycline hyclate (Harlem, 625 mg kg
-1
). Four weeks after injection, mice were euthanized 
and tumors were dissected from under the skin. All procedures performed in this study are 
















3.3 Results and Discussion 
3.3.1 SAT1 is induced by p53 
    In normal cells, the p53 protein is controlled at extremely low levels by its negative 
regulator MDM2 [144]. Nutlin, a small-molecule antagonist of MDM2, inhibits the interaction 
between p53 and MDM2, and subsequently activates the transcription of p53 downstream targets 
[145]. To identify novel metabolic targets of p53, melanoma cell line A375 expressing wild-type 
p53 was either untreated or treated with Nutlin, and total RNA derived from these cells were 
subjected to RNA sequencing. In our previous section, we have identified PHGDH from the 
RNA sequencing result as a novel metabolic target of p53 that is critical for inducing the 
apoptotic response upon serine starvation [143]. In addition, we also identified mRNA levels of 
SAT1 to be significantly up-regulated upon p53 activation (Figure 3.2A). It is well known that 
p53 can also be activated by DNA damage. To confirm that SAT1 is regulated by p53, various 
human cancer cell lines MCF7, U2OS, A375 and H1299 were either untreated or treated with 
Nutlin or DNA- damage drug doxorubicin. As a result, SAT1 mRNA levels were significantly 
up-regulated upon both Nutlin and doxorubicin treatment in cancer cell lines expressing 
wild-type p53 (U2OS, MCF7 and A375), whereas no apparent effects were detected in p53-null 
cell line H1299 (Figure 3.2B). Similarly, increase of SAT1 mRNA levels upon Nutlin treatment 
and DNA damage were also observed in human renal cell carcinoma (RCC) cell lines expressing 
64 
 
wild-type p53 (HA251, HA212 and AU-48) (Figure 3.2C). However, expression of SAT1 was not 
affected by both drugs in p53 mutant RCC cell lines (A704, SKRC-44 and SKRC-42) (Figure 
3.2C).  
To confirm that the transcription regulation of SAT1 is dependent on p53, we generated 
p53-knockout U2OS cell line using CRISPR-cas9 technology. As shown in Figure 3.3A, p53 
protein, as well as Nutlin-induced activation of downstream targets p21, TIGAR and MDM2, 
was completely abolished upon p53-knockout (p53 CRISPR). Notably, SAT1 activation was also 
abrogated in p53-knockout U2OS cells treated with Nutlin (Figure 3.3B). Together, these data 














Figure 3.2. DNA damage and Nutlin induce p53-dependent activation of SAT1. (A) 
Quantitative RT-PCR (qRT-PCR) analysis of SAT1 transcript level was performed with total 
RNAs purified from A375 cells treated with Nutlin (10μM) for the indicated times. (B) qRT-PCR 
analysis of the mRNA expression levels of SAT1 in the indicated cancer cell lines (MCF7, U2OS, 
A375, H1299) untreated (Ctrl) or treated with Nutlin (10μM) or doxorubicin (Dox) (0.2μg/mL) 
for 24 hours. (C) Indicated Renal cell carcinoma cell lines were untreated or treated with Nutlin 
(10μM) or Dox (0.2μg/mL) for 24 hours, and SAT1 mRNA levels were measured using qRT-PCR. 
All mRNA expression levels were normalized with GAPDH. Error bars represent s.d. from three 







Figure 3.3. Nutlin-induced activation of SAT1 is p53-dependent. (A) U2OS Ctrl CRISPR and 
p53 CRISPR cell lines were treated with Nutlin (10μM) for the indicated times, and total protein 
lysates were subjected to Western blotting analysis for the expression of p53, p21, TIGAR, 
MDM2 and Actin. (B) SAT1 transcript levels were measured by qRT-PCR in U2OS Ctrl CRISPR 
and p53 CRISPR cell lines treated with Nutlin (10μM) for the indicated times. All mRNA 
expression levels were normalized with GAPDH. Error bars represent s.d. from three 




3.3.2 Identification of SAT1 as a p53 target 
    To further explore whether SAT1 can be induced by exogenous p53, we established a 
Tet-on p53-inducible cell line in H1299 in which p53 expression is inducible by the addition of 
tetracycline. As expected, p53 was able to activate the expression of MDM2, TIGAR, PUMA 
(also known as BBC3) and p21 (also known as CDKN1A) (Figure 3.4A). Notably, SAT1 mRNA 
levels were also up-regulated at various time points after p53 induction (Figure 3.4B).  
The promoter region of the human SAT1 gene at chromosome Xp22.1 contains two 
potential sites that match the consensus p53-binding sequence (Figure 3.5A). Chromatin 
immunoprecipitation (ChIP) analysis of H1299 cells expressing exogenous p53 revealed 
increased binding of p53 with two indicated binding sites (Figure 3.5B). Moreover, 
overexpression of wild-type p53 by transient transfection induced the mRNA levels of SAT1, 
whereas three p53 hot-spot mutants (R175H, R273H and R248W) did not affect the expression 
of SAT1 (Figure 3.5C). Collectively, these data demonstrate that SAT1 is a novel transcriptional 












Figure 3.4. p53 induces the transcription of SAT1. (A) p53 Tet-on H1299 cells were induced 
with 0.5μg/mL tetracycline (Tet) for indicated times, and total protein lysates were analyzed by 
Western blotting using antibodies against p53, MDM2, TIGAR, PUMA, p21 and Actin. (B) SAT1 
mRNA expression levels were measured by qRT-PCR in p53 Tet-on H1299 cells induced with 
















Figure 3.5. SAT1 is a transcriptional target of p53. (A) Schematic representation of the 
promoter region in human SAT1 gene. The p53 binding sites upstream of the first exon are 
indicated as responsive elements (RE). TSS, transcription start site. (B) ChIP-qPCR was 
performed in H1299 cells transfected with empty vector (Ctrl) or p53. (C) H1299 cells were 
transfected with empty vector or increasing amount of p53 wild-type or mutant vectors (R175H, 





3.3.3 Effect of SAT1 overexpression on growth arrest, apoptosis and tumorigenesis 
    SAT1 is a key polyamine catabolism enzyme that mediates the acetylation of spermidine 
and spermine. Overexpression of SAT1 has been implicated to cause a rapid depletion of 
polyamine pool [138]. To investigate the effect of SAT1 on cell proliferation and survival in a 
physiological setting, we generated a SAT1 tetracycline-inducible (Tet-on) cell line using 
p53-null H1299 cells. Upon addition of tetracycline, both SAT1 protein and mRNA levels were 
increased in a time-dependent manner (Figure 3.6A and 3.6B). Surprisingly, no obvious growth 
arrest or cell death was observed upon SAT1 induction (Figure 3.6C). In addition, expression of 
apoptosis markers (PUMA, cleaved-caspase3 and cleaved-PARP) were not detected in cell 
lysates from Tet-on cells expressing SAT1, indicating the absence of apoptosis (Figure 3.6D).  
    To explore whether SAT1 has tumor suppressive activities in vivo, we injected the SAT1 
Tet-on H1299 cells into nude mice, and fed the mice with tetracycline-containing food to induce 
the expression of SAT1 in xenograft cells. Upon SAT1 induction, the growth of p53-null H1299 
cells was dramatically reduced in the xenograft tumor growth assay (Figure 3.7A and 3.7B). 
Notably, the expression data from Oncomine database revealed that SAT1 expression is 
down-regulated in a variety of human cancers, including invasive breast carcinoma, lung 
carcinoid tumor, B-cell acute lymphoblastic leukemia and myxoid/round cell liposarcoma 
(Figure 3.8). Further analysis of 21 pairs of human tumors versus adjacent normal tissues 
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obtained from our local tumor bank also showed that SAT1 is down-regulated in 86% of the 
human cancer specimens (6/6 kidney tumor samples, 5/5 breast tumor samples, and 7/10 colon 
tumor samples) (Figure 3.9). These data implicate that SAT1 has tumor suppressive activities 
independent of cell growth arrest and apoptosis, and that it may be a common oncogenic target 



















Figure 3.6. SAT1 overexpression does not induce growth arrest and apoptosis. (A) SAT1 
Tet-on inducible stable line cells were treated with 0.5μg/mL tetracycline for indicated times 
followed by western blot analysis. Actin was used as a loading control. (B) qRT-PCR analysis of 
mRNA levels of SAT1 in SAT1 Tet-on stable line cells at the indicated times after induction. (C) 
Representative phase-contrast images of SAT1 Tet-on stable cells un-induced or induced with 
0.5μg/mL tetracycline for 48 hours (magnification, ×10). Percentage of cell survival at the 
indicated times is shown as mean ± s.d. (D) SAT1 Tet-on stable cells were induced with 
0.5μg/mL tetracycline for indicated times, and total protein lysates were subjected to western 










Figure 3.7. SAT1 suppresses xenograft tumor growth in vivo. (A) Xenograft tumors from 
SAT1 Tet-on cells. (B) Tumor weight was determined (error bars, s.d. from four tumors in control 










Figure 3.8. SAT1 is down-regulated in human cancers. (A, B, C and D) Data-sets obtained 
from Oncomine database showing that the transcription levels of SAT1 are lower in tumors 
(cancer) than in their adjacent normal tissues (normal) in indicated cancer types. The actual fold 








Figure 3.9. SAT1 is down-regulated in tumors of human cancer patients. (A, B and C) 
Quantitative RT-PCR analysis of the expression levels of SAT1 in paired normal and cancer 
tissues from kidney (A), breast (B) and colon (C). Average expression levels from normal tissues 
were normalized to 1 in each type of cancer. Data shown in mean ± s.d. from two technical 
replicates. N, normal tissue; T, cancer tissue. 
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3.3.4 SAT1 overexpression leads to lipid peroxidation and ferroptosis upon ROS stress. 
    Our previous studies have revealed that tumor suppression mediated by p53 can occur in the 
absence of growth arrest, apoptosis and senescence [97]. Notably, p53-mediated ferroptosis in 
response to ROS stress through suppressing SLC7A11 is a novel tumor suppression mechanism 
that has been discovered recently [81]. In fact, polyamine metabolism has  been implicated to 
be involved in ROS stress response, as the natural polyamine spermine can function as a free 
radical scavenger, while catabolization of polyamine by SAT1 and polyamine oxidase (PAO) 
gives rise to H2O2 and increase oxidative stress [146-148]. Nevertheless, the cell death response 
upon SAT1 expression in the setting of oxidative stress exposure is unexplored. To evaluate 
whether SAT1 overexpression modulates ROS stress response, we treated SAT1 Tet-on cells with 
ROS inducing agent tert-butyl hydroperoxide (TBH) as previously described [149]. As shown in 
Figure 3.10, no obvious cell death was observed upon either SAT1 induction or ROS treatment 
alone. However, the combination of SAT1 induction and ROS treatment induced significant cell 
death (Figure 3.10). The mode of cell death was then confirmed by treatment of different cell 
death inhibitors. Notably, Ferrostatin-1 (Fer-1), a specific ferroptosis inhibitor, completely 
rescued SAT1 and ROS-induced cell death. In contrast, inhibitors of apoptosis (Z-VAD-fmk), 
necroptosis (necrostatin-1) and autophagy (3-methylademine) failed to suppress cell death 
(Figure 3.10). This demonstrated that SAT1 expression triggers ferroptosis upon ROS stress. 
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Notably, the up-regulation of Ptgs2 has recently been identified to be a potential molecular 
marker of ferroptosis by Stockwell’s lab [150]. We therefore examined Ptgs2 levels in xenograft 
tumors. Indeed, Ptgs2 was found to be significantly up-regulated in the tumors when SAT1 was 
induced, suggesting that ferroptosis is involved in tumor suppression (Figure 3.11). 
Previous studies have indicated that lipid peroxidation is a crucial event on cell membrane 
that leads to ferroptosis [84]. We then examined lipid ROS levels in SAT1 Tet-on cells upon 
SAT1 induction and ROS treatment. As a result, SAT1 induction alone only had modest effect on 
lipid ROS, and ROS treatment alone elevated lipid ROS level by 4-fold (Figure 3.12A and 
3.12B). However, the lipid ROS level was increased by 9-fold upon concomitant SAT1 induction 
and ROS treatment (Figure 3.12A and 3.12B). In contrast, no differences in cellular ROS levels 
were observed between cells with ROS treatment alone and those with the addition of SAT1 
induction (Figure 3.12C and 3.12D). Taken together, these data demonstrate that SAT1 













Figure 3.10. SAT1 overexpression leads to ferroptosis upon ROS stress. (A) Representative 
phase-contrast images of SAT1 Tet-on cells treated with 0.5μg/mL tetracycline and 60μM TBH 
for 24 hours. The images also show cells treated with tetracycline and TBH with the addition of 
specific cell death inhibitors for 24 hours. Z-VAD-fmk, a caspase inhibitor, 10μg/mL; 
Necrostatin 1 (Nec-1), a necroptosis inhibitor, 10μg/mL; Ferrostatin-1 (Fer-1), a ferroptosis 
inhibitor, 2μM; 3-methyladenine (3-MA), an autophagy inhibitor, 2mM. (B) The percentages of 











Figure 3.11. Ferroptosis marker Ptgs2 is up-regulated in xenograft tumors with SAT1 
induction. The mRNA levels of Ptgs2 was determined by qRT-PCR analysis in 4 xenograft 
tumors without SAT1 induction and 6 xenograft tumors with SAT1 induction. Data is shown as 













Figure 3.12. SAT1 overexpression increases lipid peroxidation upon ROS stress. (A and C) 
Lipid and cytosolic ROS production in SAT1 Tet-on cells treated with tetracycline and TBH for 
24 hours were assessed by flow cytometry using C11-BODIPY and H2DCFDA. (B and D) 
Quantification of lipid and cytosolic ROS levels from three representative experiments are 
shown (mean ± s.d.) *** is used to indicate statistical significance corresponding to P value < 




3.3.5 SAT1 contributes to p53-mediated ferroptosis upon ROS stress 
Our results that SAT1 is a novel transcriptional target of p53 implicate that SAT1 may 
contribute to p53-mediated ferroptotic cell death and ROS response. To test our hypothesis, we 
established a SAT1-knockout CRISPR-cas9 cell line in p53 wild-type U2OS cells. Because the 
SAT1 antibody could not detect endogenous SAT1 protein, we designed a qRT-PCR primer in 
between the targeting regions of two guide RNAs, therefore were able to confirm knockout 
efficiency through qRT-PCR. As shown in Figure 3.13A, the mRNA levels of SAT1 were 
markedly increased when p53 is activated by Nutlin in mock-knockout U2OS cells (Ctrl 
CRISPR). In contrast, SAT1 expression was undetectable with or without Nutlin treatment in 
SAT1-knockout U2OS cells (SAT1 CRISPR) (Figure 3.13A). Notably, SAT1 deficiency did not 
affect p53-mediated growth arrest and apoptosis, as the expression of p21 and PUMA in 
response to the Nutlin treatment were not changed upon SAT1-knockout (Figure 3.13B). To 
evaluate the role of SAT1 in p53-mediated ferroptosis, U2OS mock-knockout and 
SAT1-knockout cells were treated with Nutlin and ROS. Consistent with our previous results, 
Nutlin or ROS treatment alone failed to elicit a cell death response, whereas combination 
treatment with both Nutlin and ROS induced massive ferroptotic cell death in mock-knockout 
U2OS cells (Figure 3.14). Notably, the cell death was significantly abrogated upon knockout of 
SAT1, indicating that p53-mediated activation of SAT1 contributes to ferroptotic cell death in the 
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Figure 3.13. SAT1 knockout does not affect p53-mediated cell cycle arrest and apoptosis. (A) 
qRT-PCR analysis of SAT1 mRNA levels in U2OS control (Ctrl) CRISPR and SAT1 CRISPR 
stable cell lines treated with 10μM Nutlin for indicated times. (B) U2OS control CRISPR and 
SAT1 CRISPR stable cell lines were treated with 10μM Nutlin for indicated times, and total 
protein lysates were subjected to western blot analysis for the expression of p53, PUMA, p21 












Figure 3.14. SAT1 contributes to p53-mediated ferroptosis upon ROS stress. (A) U2OS 
control CRISPR and SAT1 CRISPR cells were treated with 10μM Nutlin and 350μM TBH for 24 
hours when images were taken. (B) Quantification of cell death in Figure 3.14A from three 
technical triplicates (mean ± s.d.) is shown. *** is used to indicate statistical significance 






Previously, a p53 acetylation-deficient mutant p53
3KR
(K117/161/162R) was found to retain 
the ability to promote ferroptosis [81]. Moreover, mice that harbor these mutations still retain 
intact tumor suppression [97]. Therefore, we examined the levels of Sat1 transcripts in mouse 






 mice. qRT-PCR 





in response to Nutlin treatment, whereas no change was observed in p53
-/-
 MEFs (Figure 3.15A). 
In addition, knock-down of Sat1 by siRNA in p53
3KR/3KR
 MEFs partially rescued ROS-induced 
ferroptosis, suggesting that SAT1 contributes, at least in part, to p53
3KR
-mediated ferroptotic 
responses (Figure 3.15B-D). Collectively, these data implicate that p53-mediated regulation of 














Figure 3.15. SAT1 contributes to p53-3KR-mediated ferroptosis upon oxidative stress. (A) 
MEFs from indicated genotype were treated with 10μM Nutlin, and Sat1 transcript levels were 
measured by qRT-PCR. (B) qRT-PCR analysis of SAT1 mRNA levels in p53
3KR/3KR
 MEFs 
transfected with control siRNA or SAT1 siRNA for 48 hours. (C) p53
3KR/3KR
 MEFs were 
transfected with control siRNA or SAT1 siRNA for 48 hours, and then treated with TBH (150μM) 
for 24 hours before images were taken. (D) Quantification of cell death in Figure 3.15C from 
three technical triplicates (mean ± s.d.) is shown.  
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3.3.6 Molecular mechanism of SAT1-induced ferroptosis 
    Although the mechanism of SAT1-induced ferroptosis upon ROS stress is yet unknown, 
there were some studies implicating that polyamine metabolism pathway could regulate histone 
modification, and therefore, alter gene expression [151, 152]. We hypothesized that SAT1 
regulates ferroptosis through modulating the expression of components in the ferroptosis 
pathways. GPX4 is a glutathione peroxidase that functions as a central regulator of ferroptosis. 
Inhibition of GPX4 has been implicated to increase the level of lipid peroxidation and lead to 
ferroptosis [150]. Therefore, we examined GPX4 expression levels in SAT1 Tet-on cells. 
However, no changes were observed at both the protein and mRNA levels of GPX4 upon SAT1 
induction and ROS treatment (Figure 3.16). Our previous studies have also identified 
p53-mediated transcriptional repression of SLC7A11, a component of the cystine/glutamate 
antiporter found to be critical for ROS-induced ferroptosis [81]. Again, overexpression of 
SLC7A11 did not rescue SAT1-induced ferroptosis upon ROS stress, indicating that SAT1 














Figure 3.16. SAT1 does not affect GPX4 expression. (A) SAT1 Tet-on cells were treated with 
tetracycline and TBH, and total cell lysates were subjected to western blot analysis for the 
expression of GPX4. Actin was used as a loading control. (B) qRT-PCR analysis of GPX4 

















Figure 3.17. SLC7A11 overexpression does not rescue SAT1-induced ferroptosis upon ROS. 
(A) Representative phase-contrast images of SAT1 Tet-on cells transfected with empty vector or 
vector expressing SLC7A11 followed by treatment of tetracycline and TBH (60μM) for 24 hours. 
(B) Quantification of cell death is shown in mean ± s.d. from three technical triplicates. NS 






Notably, lipid peroxidation is a critical event on cell membrane that leads to ferroptosis, and 
studies have revealed that arachidonate 15-lipoxgenase (ALOX15) is specifically responsible for 
oxidative stress-induced cell death among lipoxygenase family [153]. Interestingly, ALOX15 
expression levels were elevated upon SAT1 induction or with combination of ROS treatment, 
whereas no increase in levels were observed in the other two lipoxygenases (ALOX5, 
5-lipoxygenase and ALOX12, 12-lipoxygenase) (Figure 3.18). In addition, SAT1 and 
ROS-induced ferroptosis was completely abrogated by PD146176, an ALOX15-specific inhibitor 
[154] (Figure 3.19A and 3.19B). Furthermore, induction of ALOX15 expression level was also 
partially attenuated upon SAT1 knockout after p53 activation via Nutlin, suggesting that 
ALOX15 is a downstream effector of p53-induced SAT1 (Figure 3.19C). Taken together, these 















Figure 3.18. SAT1 induces the expression of ALOX15. (A) qRT-PCR analysis of ALOX15 
mRNA levels in SAT1 Tet-on cells treated with tetracycline and TBH. (B) SAT1 Tet-on cells were 
induced with 0.5μg/mL tetracycline for the indicated times, and ALOX15 mRNA levels were 
examined using qRT-PCR. (C and D) qRT-PCR analysis of ALOX5 and ALOX12 mRNA levels 








Figure 3.19. ALOX15 is a mediator during SAT1-induced ferroptosis upon ROS. (A) 
Representative phase-contrast images of SAT1 Tet-on cells treated with tetracycline and TBH 
with the addition of ferroptosis inhibitor (Fer-1) or ALOX15 inhibitor (PD146176). (B) The 
percentages of cell death were measured by trypan blue exclusion assay. (C) U2OS control 
CRISPR and SAT1 CRISPR cells were treated with 10μM Nutlin or 350μM TBH for 24 hours, 
and total RNA was extracted for the analysis of ALOX15 mRNA levels using qRT-PCR. Data is 
shown in mean ± s.d. from three technical triplicates. * is used to indicate statistical significance 











Dissecting the role of acetylation  












4.1 Background and Rationale 
Our studies on PHGDH and SAT1 led us to the question of how p53 differentially regulates 
a diverse array of downstream targets, and which functions of p53 contribute to p53-mediate 
tumor suppression. It is well-known that p53 activity is regulated by a complex network of 
fine-tuning mechanisms that include p53 stabilization, co-activator and repressor recruitment, 
and varieties of post-translational modifications, including ubiquitination, phosphorylation, 
acetylation, sumoylation, methylation, and neddylation [16]. Specifically, acetylation of p53 is 
indispensible for p53 activation, and is demonstrated to play a major role in differential 
regulation of downstream targets during stress responses [155]. Previous studies have revealed 
that acetylation at K120 by Tip60/MOF is critical for p53-mediated apoptotic responses [156, 
157], while acetylation at K164 by CBP/p300, along with K120 acetylation, contributes to both 
p53-mediated cell cycle arrest and apoptosis [155]. More recently, we generated p53
3KR/3KR
 
knock-in mice in which acetylation at K117, K161, and K162 in mouse p53 (homologous to 
K120 and K164 in human p53) were abrogated by replacing the lysine residues with arginine. As 
a result, p53
3KR/3KR
 mice completely lost p53-induced growth arrest, apoptosis, and senescence 
functions in response to cellular stresses [97]. Surprisingly, unlike p53-null mice which develop 
early onset spontaneous tumors, all of the p53
3KR/3KR
 mice remain tumor free [97]. These results 
indicate that the apoptosis, growth arrest, and senescence functions of p53 are dispensable for 
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p53 to execute its tumor suppressive effect and other aspects of p53 function are sufficient to 
suppress tumor formation. Notably, p53
3KR
 retains the ability to regulate energy metabolism and 
reactive oxygen species production through transcription regulation of metabolic targets such as 
TIGAR, GLS2, and GLUT3 [97]. Our most recent study also demonstrated that p53
3KR
 retains 
the capacity to promote ferroptosis, a non-apoptotic, iron-dependent and oxidative cell death, 
through repressing the expression of SLC7A11, a key component of the cystine/glutamate 
antiporter [81]. Moreover, our study in Section 3 clearly indicated that SAT1, a novel 
p53-regulated gene in polyamine metabolism and ferroptosis, can also be induced by p53
3KR
. 
These results imply that ferroptotic cell death pathway may constitute a potential mechanism of 
p53-mediated tumor suppression.  
Notably, p53 also regulates mTOR signaling pathway. mTOR is a central regulator of cell 
growth and proliferation in response to nutrients, growth factors, energy metabolism and hypoxia 
[158]. It is an evolutionarily conserved serine-threonine protein kinase that belongs to the 
phosphoinositide 3-kinase (PI3K)-related kinase family [159]. mTOR is regulated by a group of 
tumor suppressors and oncogenes, and alterations in mTOR signaling pathway are associated 
with cancer development. In response to growth factors such as IGF-1, mTOR is activated 
through a kinase cascade consisting of PI3K, PDK1, and AKT, which is negatively regulated by 
tumor suppressor PTEN [91]. Whereas in response to low energy levels, mTOR is inhibited by 
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adenosine monophosphate (AMP)-dependent kinase (AMPK), which is activated by tumor 
suppressor LKB1 [160]. Additionally, hypoxia signaling also inhibits mTOR through activating 
the expression of DNA damage inducible transcript 4 (DDIT4) [161]. Notably, the regulations of 
mTOR through these signaling pathways are all via tumor suppressor tuberous sclerosis 1 and 2 
complex (TSC1/2), which negatively regulates mTOR. Mutations in TSC2 leads to tuberous 
sclerosis syndrome associated with an increased risk of renal cell carcinoma (RCC) [160]. PTEN 
mutation or deletion, which result in constitutive activation of AKT and mTOR signaling, are 
found in a number of cancers including hepatocellular carcinoma, glioblastoma, lung carcinoma 
and melanoma [162, 163]. It is well-known that mTOR activation increases the phosphorylation 
of its downstream targets, and regulates a variety of cellular processes including translation, 
ribosome biogenesis, and inhibition of autophagy, all of which promote cell growth and 
proliferation. The p70S6 kinase (p70S6K) and eIF4E binding protein 1 (4EBP1) are two most 
well-characterized mTOR targets that are involved in translation regulation. mTOR 
phosphorylates p70S6K and 4EBP1, and increases the level of translation [164]. Interestingly, 
genes coding for S6K and eIF4E are found be to be amplified in several types of human cancers, 
and overexpression of eIF4E results in increased frequency of tumor formation, suggesting that 
mTOR signaling pathway is closely related with cancer development [165-167]. Notably, the 
expression of several negative regulators of mTOR, including DDIT4, TSC2, PTEN, AMPKβ1, 
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and IGF-BP3, are directly activated by p53, resulting in inhibition of mTOR by p53 [92]. 
Moreover, recent studies have revealed that SESN2 (a gene coding for Sestrin2) is a 
p53-inducible target upon genotoxic stress that inhibits mTOR signaling through activation of 
AMPK and TSC2 phosphorylation [168].  
Given that cell cycle arrest and pro-apoptotic target genes of p53 are regulated by 
acetylation at K120 and K164, we postulated that additional modifications may exist that are 
crucial for the regulation of non-canonical p53 targets. In this section, we identified two novel 
p53 acetylation sites at lysine K101 and K139 within the human p53 DNA-binding domain. Both 
lysine residues are evolutionarily conserved and are homologous to lysine K98 and K136 in 
mouse p53. Ablation of K98 or K136 acetylation alone has very modest effects on p53-mediated 







) significantly abrogated p53-mediated activation of 






 are all 
defective in inducing ferroptosis upon oxidative stress. Similar to p53
-/-
mice, all of the p53
5KR/5KR
 





 mice developed spontaneous tumors within 18 months of age, 





has lost the ability to induce ferroptosis, it still retains the activity to 
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inhibit mTOR signaling through activating the expression of two mTOR negative regulators, 
Sestrin2 and DDIT4. Our studies suggest that p53-mediated ferroptosis is a critical barrier to 
prevent tumor formation. However, in the absence of cell cycle arrest, apoptosis and ferroptosis, 
p53-mediated regulation of the nutrient-sensing mTOR signaling pathway may play an important 





















4.2 Materials and Methods 
Protein purification and mass spectrometry 
    Acetylated p53 protein was purified for mass spectrometry analysis to identify novel 
acetylation sites. In general, H1299 cells were co-transfected with vectors expression 
Flag-tagged p53, HA-CBP and Tip60 for 16 hr, and then treated with 5 mM nicotinamide and 1 
μM TSA for 8 hr. Cells were harvested and lysed in Flag-lysis buffer with fresh proteinase 
inhibitor cocktail, 10 mM nicotinamide, and 2 mM TSA. The cell extracts were then 
immunoprecipitated with M2 beads and eluted with Flag peptide (Sigma). The eluted sample was 
resolved on 4%–20% Tris-glycine SDS-PAGE (Invitrogen), and the p53 bands were excised and 
subjected to mass spectrometric analysis. 
Plasmids, transfection and immunoprecipitation 







(K120/139/164R+6KR), and mouse p53
K98R
 were derived from pCIN4-Flag-p53 or 
Topo-Flag-mp53 by mutagenesis using QuickChange Site-Directed Mutagenesis Kit (Stratagene) 
according to manufacturer’s protocol. Tet-on inducible mouse p53 mutant constructs were 
generated by sub-cloning mutant p53 from Topo vector into pTRIPZ tetracycline-inducible 
vector (Thermo). All transfections were performed using Lipofectamine2000 (Invitrogen) 
according to manufacturer’s protocol. To detect p53 acetylation on lysine K101 or K139, p53 
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protein was immunoprecipitated with M2 beads, eluted with Flag peptide, resolved on 
SDS-PAGE, and detected by α-AcK101 p53 antibody or α-AcK139 p53 antibody.   
Cell culture and stable lines 
    All cells were cultured in 37°C incubator with 5% CO2. H1299 cell lines were cultured in 
DMEM supplemented with 10% fetal bovine serum (FBS), 100 units per ml penicillin and 100 
μg/ml streptomycin (all Gibco). MEFs were generated from day 13.5 embryos according to 
standard procedures. FBS used for MEFs was heat-inactivated and supplemented with 1% 
non-essential amino acids. Tet-on inducible H1299 stable cell lines expressing mouse p53 
mutants were generated by transfecting pTRIPZ-mp53 mutant constructs into H1299 cells, 
followed by puromycin selection (1μg/mL) for 14 days. Established Tet-on inducible cell lines 
were maintained in DMEM with 10% Tet-free FBS (Clonetech). To induce the expression of p53, 
0.5 μg/mL of tetracycline was added into culture medium.  
Western blotting and antibodies 
    Cell lysates were prepared in Flag lysis buffer with fresh protease inhibitor cocktail. Protein 
extracts were analyzed by western blotting according to standard protocols using primary 
antibodies specific for human p53 (DO-1, Santa Cruz), α-AcK101 p53 (custom made by PTM), 
α-AcK139 p53 (custom made by PTM), mouse p53 (CM5, Leica biosystems), MDM2 (Ab5, 
Millipore), TIGAR (E2, Santa Cruz), p21 (SX118, Santa Cruz), Actin (A3853, Sigma-Aldrich), 
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Phospho-p70 S6 Kinase (Thr389, Cell Signaling Technologies), p70 S6 Kinase (49D7, Cell 
Signaling Technologies), Phospho-4E-BP1 (Ser65, Cell Signaling Technologies), 4E-BP1 (Cell 
Signaling Technologies), and DDIT4 (10638-1-AP, Proteintech). HRP-conjugated anti-mouse 
and anti-rabbit secondary antibodies (GE Healthcare) were used and signals were detected on 
autoradiographic films with Pierce ECL western blotting detection system or SuperSignal West 
Dura reagents (Thermo scientific).  
RNA extraction and qRT-PCR 
    Total RNA was extracted using TRIzol Reagent (Life Technologies) according to 
manufacturer’s protocol. cDNA was synthesized from total RNA using M-MulV Reverse 
Transcriptase kit (NEB). PCR analysis was performed using Applied Biosystems 7500 Fast 
System. For the qRT-PCR analysis of human transcripts the following primers were used:  
TIGAR forward 5’ -CTCAAGACTTCGGGAAAGGA- 3’, 
TIGAR reverse 5’ -GGTGTAAACACAGGGCACTCTT- 3’, 
SAT1 forward 5’ -CCGTGGATTGGCAAGTTATT- 3’,  
SAT1 reverse 5’ -TCCAACCCTCTTCACTGGAC-3’,  
SLC7A11 forward 5’ -ATGCAGTGGCAGTGACCTTT- 3’, 
SLC7A11 reverse 5’ -GGCAACAAAGATCGGAACTG- 3’, 
SESN2 forward 5’ -CGCTTTGAGCTGGAGAAGTC- 3’, 
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SESN2 reverse 5’ -TCCACAAAGCACAGCATGTC- 3’, 
DDIT4 forward 5’ -CTGGACAGCAGCAACAGTG- 3’, 
DDIT4 reverse 5’ -ACACCCCATCCAGGTAAGC- 3’, 
GAPDH forward 5’ -ATCAATGGAAATCCCATCACCA- 3’,  
GAPDH reverse 5’ -GACTCCACGACGTACTCAGCG- 3’.  
For the qRT-PCR analysis of mouse transcripts the following primers were used:  
Sesn2 forward 5’ -CAGCGCTTTCATTCCAGTG- 3’, 
Sesn2 reverse 5’ -CCGGGTGTAGACCCATCA- 3’, 
Ddit4 forward 5’ -CCAGAGAAGAGGGCCTTGA- 3’, 
Ddit4 reverse 5’ -CCATCCAGGTATGAGGAGTCTT- 3’. 
Cell death count, drug and inhibitors 
    Cell death was determined by trypan blue assay. Erastin was used at a concentration of 1µM 









4.3 Results and Discussion 
4.3.1 p53 is acetylated at lysine K101 and K139 residues by CBP and Tip60 
To screen for novel p53 acetylation sites, we purified ectopically expressed p53 protein in 
p53-null H1299 cells with the presence of two major p53 acetyltransferases CBP and Tip60, and 
analyzed the post-translational modifications of p53 using mass spectrometry. Our mass 
spectrometry data revealed two previously uncharacterized p53 acetylation sites at lysine residue 
K101 and K139, both located in p53 DNA-binding domain (Figure 4.1A and 4.2A). K101 and 
K139 lysine residues are both evolutionarily conserved, and are homologous to the K98 and 
K136 lysine residues in mouse p53 respectively (Figure 4.1B and 4.2B). To validate the 
acetylation at K101, we generated a rabbit monoclonal antibody specifically against p53 
acetylated at lysine K101. We first transfected H1299 p53-null cells with vectors expressing 
either Flag-tagged wild-type p53 or K101R p53 in the absence or presence of acetyltransferases 
CBP or Tip60, and the tagged p53 was immunoprecipitated and resolved on SDS-PAGE for 
western blot analysis. The site-specific AcK101-p53 antibody only recognized wild-type p53 
acetylated by CBP, but not acetylation-deficient K101R p53 mutant (Figure 4.1C). Furthermore, 
Tip60 does not acetylate p53 at K101 either (Figure 4.1C). A similar experiment was performed 
using mouse p53, and the AcK101-p53 antibody also recognized acetylation of mouse p53 at 
K98 in the presence of CBP (Figure 4.1D). Together, these results indicate that K101 lysine 
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residue of p53 is a bona fide acetylation site of CBP. Similarly, to validate the acetylation at 
K139, we generated a rabbit polyclonal antibody against acetylated p53 at lysine 139 
(AcK139-p53). Because the AcK139-p53 antibody has cross-reactivity with acetylated lysine 
K120, K164, and six C-terminal acetylation sites, we then compared the signal detected between 
the acetylation-deficient mutant p53
8KR
 (K120/164R+6KR) and p53
9KR
 (K120/139/164R+6KR). 




 in the absence or 
presence of acetyltransferase Tip60, and the tagged p53 were immunoprecipitated for western 
blot analysis on SDS-PAGE. As shown in Figure 4.2C, the AcK139-p53 antibody only 
recognized p53
8KR
 acetylated by Tip60, but not p53
9KR
. This result indicates that K139 of p53 is 













Figure 4.1. Acetylation of Human p53 at K101 and Mouse K98 by CBP. (A) Mass 
spectrometry of purified p53 protein in the presence of CBP uncovered acetylation of p53 at the 
K101 lysine residue. (B) Cartoon figure depicting the K101 lysine residue (K98 for mouse p53) 
located in the N-terminal end of the DNA-binding domain. (C) H1299 cells were transfected 
with vectors expressing either Flag-tagged human wild-type or K101R mutant p53 in the 
presence of CBP and Tip60. Whole-cell lysates were collected, and Flag-tagged p53 was 
immunoprecipitated using M2 Flag beads. K101-acetylated p53 was detected using site-specific 
antibody. (D) Similar experiment to (C) was performed using Flag-tagged mouse wild-type or 
K98R mutant p53 in the presence of CBP, and p53 acetylation at K98 was detected using the 







Figure 4.2. Lysine K139 in Human p53 (K136 in Mouse p53) is a novel acetylation site 
acetylated by Tip60. (A) Mass spectrometry of purified p53 protein in the presence of CBP and 
Tip60 uncovered acetylation of p53 at the K139 lysine residue. (B) Schematic representations of 
human and mouse p53 protein depicting the K139 lysine residue (K136 for mouse p53) located 
in DNA-binding domain. (C) H1299 cells were transfected with vectors expressing either 
Flag-tagged human 8KR or 9KR mutant p53 in the presence of Tip60. Flag-tagged p53 was 
immunoprecipitated using M2 beads, and K139-acetylated p53 was detected with site-specific 





4.3.2 Simultaneous loss of acetylation at K117/161/162 with K98 or K136 impairs p53 
transcriptional activities 
Our previous studies have shown that ablation of acetylation in human K120/164 or mouse 
K117/161/162 abrogates p53’s ability to transactivate target genes involved in growth arrest, 
apoptosis, and senescence. However, the acetylation-deficient mutant mouse p53
3KR
 
(K117/161/162R) retains the regulation on metabolic targets such as TIGAR, and ferroptosis 
target SLC7A11. Thus, we wish to investigate whether ablation of K98 or K136 acetylation 
would further impair p53’s transcription activity. Most recently, we have revealed that loss of 
K98 acetylation (p53
K98R
) alone has very modest effect on p53-mediated transactivation. 
However, simultaneous mutations at all four acetylation sites K98/117/161/162 (p53
4KR98
) 
completely abolish its ability to regulate TIGAR and SLC7A11. Similarly, to evaluate the effect of 







 (3KR+K136R), and cell lysates were collected and resolved on 
SDS-PAGE for western blot analysis. As a result, ectopic expression of p53
K136R
 showed 
comparable transcriptional activity with wild-type p53 on target genes such as MDM2, TIGAR, 
and p21 (Figure 4.3A). However, simultaneous mutations of K117/161/162 and K136 result in 
significant defect in transactivating Mdm2 and Tigar expression (Figure 4.3A). Furthermore, we 












The p53 mutants were then induced by the addition of tetracycline (Tet-on), and downstream 







 all lost the ability to transcriptionally activate the expression of TIGAR, 
SAT1, and repress the expression of SLC7A11. Interestingly, our previous data demonstrated that 





 were all able to recruit to the TIGAR gene promoter to the similar extent. To further 




, we performed chromatin 
immunoprecipitation assay in H1299 cells transfected with various acetylation-deficient mutants. 




 were able to bind to TIGAR and SLC7A11 gene promoters 
to the same extent as p53
3KR
 (Figure 4.4). Taken together, these data indicate that K98 and K136 
acetylation in the p53 DNA-binding domain control p53 transcriptional activity without affecting 












Figure 4.3. Simultaneous loss of acetylation at K117, K161, K162 with K98 or/and K136 
abolishes p53’s ability to regulate TIGAR, SAT1, and SLC7A11. (A) H1299 cells were 
transfected with empty vector and vectors expressing wild-type, 3KR, K136R, or 4KR136 
mutant p53. Expression of MDM2, TIGAR, and p21 were detected via western blot analysis. 
(B-D) H1299 inducible p53 stable cell lines expressing wild-type, 3KR, 4KR98, 4KR136, or 
5KR p53 were treated with doxycycline for indicated times, and transcription levels of p53 target 












Figure 4.4. Effect of K98 and K136 acetylation on DNA binding capacity of p53. (A) ChIP 







. The immunoprecipitated DNA was amplified by PCR using primers that 
span the p53-binding region on TIGAR and SLC7A11 promoter, and the PCR products were 

















Our recent study has revealed that p53
4KR98
 is defective in p53-mediated ferroptotic 




 also lost the ability to induce ferroptosis, 
we performed ferroptosis assay in Tet-on inducible cell lines treated with ferroptosis inducer 
Erastin. As expected, H1299 cells expressing p53
3KR
 underwent significant ferroptosis upon 




 were resistant to Erastin and 
did not result in any cell death (Figure 4.5). This result indicates that p53-mediate ferroptotic 























 lost the ability to regulate ferroptosis upon oxidative stress. 
(A) Representative phase-contrast images of Tet-on inducible H1299 cells expressing 3KR, 
4KR136 or 5KR p53 treated with doxycycline (Tet-on), Erastin, or doxycycline + Erastin (Tet-on 
+ Erastin) for 48 hr. (B) Quantification of ferroptotic cell death in (A) from three technical 









 knock-in mice lost intact tumor suppression, but 
displayed delayed tumor onset comparing to p53
5KR/5KR
 mice 
    To ascertain whether ferroptosis or other non-canonical functions of p53 are required for 






 knock-in mice, 







Notably, although 3 of the 27 p53
3KR/3KR
 mice developed tumors, sequence analysis revealed that 





 retains intact tumor suppression activity [97]. Surprisingly, unlike 
p53
3KR/3KR
 mice, 72% of the p53
4KR98/4KR98
 mice, 55% of the p53
4KR136/4KR136
 mice, and all of the 
p53
5KR/5KR
 mice developed spontaneous tumors and died before 18 months of age (Figure 4.6). 
This result indicates that p53-mediated ferroptosis may function as a critical barrier to prevent 
tumor formation in the absence of cell cycle arrest, apoptosis, and senescence in p53
3KR/3KR
 mice. 







 mice result in loss of intact tumor suppression.  




 mice was 
significantly delayed for 6 months comparing with that in p53
5KR/5KR
 mice (Figure 4.6). This 




 mutants still have some remaining functions that may 













 knock-in mice lost intact tumor suppression, 
but displayed delayed tumor onset comparing to p53
5KR/5KR
 mice. (Data from Dr. Nin Kong) 
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4.3.5 Regulation of mTOR signaling pathway is retained by p53
4KR98
, but not by p53
5KR
 




 have very similar transcriptional activities and tumor 
suppressive properties, indicating that acetylation at lysine K98 and K136 may have functional 
redundancies. To elucidate which remaining targets of p53 are retained in p53
4KR
, we compared 




 MEFs upon the treatment of DNA 
damaging drug Etoposide using RNA-seq. RNA-seq result uncovered two target genes- SESN2 
and DDIT4, that can still be transactivated by p53
4KR98
, but not by p53
5KR
. We then further 
validated the transcriptional regulation of SESN2 and DDIT4 by various p53 
acetylation-deficient mutants in H1299 Tet-on inducible cell lines and MEFs. mRNA expression 




 induction were both elevated in a 
time-dependent manner, whereas the expression of these two genes after p53
5KR
 induction 
remained unchanged (Figure 4.7A and 4.7B). Similarly, p53
4KR98/4KR98
 MEFs treated with 
Etoposide for 24 hours showed an elevation of both Sesn2 and Ddit4 transcript levels; whereas 
p53
5KR/5KR
 MEFs undergoing the same treatment had no change in Sesn2 and Ddit4 mRNA levels 
(Figure 4.7C and 4.7D). Since Sestrin2 and DDIT4 are both negative regulators of mTOR, we 
speculate if p53
4KR98
 also repress mTOR signaling. Phosphorylation of p70S6K and 4EBP1 are 
induced by mTOR, and are used as two important indicators of mTOR activation. As shown in 
Figure 4.8, Etoposide treatment for 24 hours significantly reduced the levels of p70S6K 
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phosphorylation and 4EBP1 phosphorylation in p53
4KR98/4KR98
 MEFs, but not in p53
5KR/5KR
 MEFs. 
Taken together, these results demonstrate that p53
4KR98
 retains the ability to inhibit mTOR 
signaling, and this remaining activity may contribute to the observed delay of tumorigenesis in 
p53
4KR98/4KR98 









. (A and B) H1299 inducible p53 stable cell lines expressing 3KR, 4KR98, or 
5KR p53 were treated with doxycycline for indicated times, and expression levels of SESN2 and 





 MEFs either untreated or treated with 20μM Etoposide (Etp) for 








Figure 4.8. Regulation of mTOR signaling pathway is retained by p53
4KR98







 MEFs were treated with 20μM Etoposide for 24 hr, and 
crude cell lysates were obtained for the western blot analysis using antibodies against 

























    p53 is a bona fide tumor suppressor and serves as a guardian of the genome to prevent 
malignant transformation. It mainly functions as a transcription factor to monitor signaling 
pathways through transcriptional regulation of target genes involved in cell cycle arrest, 
apoptosis, and senescence [121]. In our studies, we have uncovered diverse array of 
p53-mediated cellular functions, including serine metabolism, polyamine metabolism, ferroptosis, 
and regulation of mTOR signaling pathway, which may contribute significantly to the tumor 
suppressive activity of p53. 
5.1 PHGDH is a novel p53 target in serine metabolism 
    Although p53 is well known for its transcriptional activation function, there are more and 
more studies suggesting that p53 is also able to repress gene transcription, and that such 
regulation is important for its ability to regulate cell death and metabolism [169, 170].  In this 
study, we identified that PHGDH, the key serine metabolism gene, is a repression target of p53 
and mediates its apoptotic response upon serine starvation. PHGDH has recently been shown to 
play an important role in tumor development, and is frequently amplified or over-expressed in 
melanoma, a type of skin cancer that rarely has p53 mutations. Here in melanoma cell lines, we 
demonstrated that PHGDH mRNA and protein levels were significantly down-regulated in 
response to Nutlin-3 and DNA-damaging agents in a p53-dependent manner. Furthermore, we 
found a p53 consensus sequence in the PHGDH promoter region, and therefore, p53 directly 
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binds to this response element to repress gene transcription. Although the precise mechanisms of 
transcription repression remain largely unknown, a number of studies suggest that p53 represses 
gene transcription through interfering with the functions of DNA-binding transcriptional 
activators, or recruiting transcriptional repressors,  such as histone deacetylases [171]. 
Therefore, it would be interesting to explore whether histone deacetylase inhibitors, such as 
trichostatin A (TSA), can block p53-mediated transcriptional repression of PHGDH.     
    PHGDH catalyzes the first and rate-limiting step in the serine synthesis pathway [116]. In 
light of the recent findings that some melanoma and breast cancer cell lines with amplified 
PHGDH locus are highly dependent on PHGDH expression for their proliferation [110, 111], 
PHGDH inhibitors are being developed (in preclinical studies) to treat these types of cancers 
[172]. In our study, we revealed that a combination of PHGDH depletion and serine starvation 
not only inhibits proliferation, but also induces significant apoptosis in melanoma cells. We also 
demonstrated that the mechanisms underlying apoptosis triggered by inhibiting PHGDH in the 
presence of serine starvation is mediated through ATF4-dependent, but p53-independent Puma 
and Noxa activation. These results imply that inhibitors of serine metabolism, when utilized in 
the setting of appropriate nutrient (specifically serine) restriction, may have therapeutic potential 
against cancer.    
Given our results showing that PHGDH is a novel repression target of p53, activators of p53 
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can be used to inhibit PHGDH expression. Nutlin-3 is a non-genotoxic drug that specifically 
activates p53 transcription through disrupting its interaction with Mdm2. However, Nutlin-3 is 
not an ideal drug for eradicating melanoma cells that retain wild-type p53, because it only 
induces p53-mediated cell cycle arrest without triggering apoptosis [125]. Thus, the possibility of 
reactivating the apoptotic function of p53 in melanoma cell lines could have profound 
implications in future therapeutic directions [108, 109]. Here, we have identified a novel p53 
downstream pathway that modulates serine metabolism, which can sensitize melanoma cells to 
apoptosis. As shown in the proposed model in Figure 5.1, activation of p53 in melanoma cell 
lines by Nutlin-3 can suppress PHGDH expression through transcriptional repression. Under 
normal condition in which serine is present, activation of p53 by Nutlin-3 only induces cell cycle 
arrest through p21 activation and PHGDH down-regulation. However, in metabolic stress 
condition in which serine is absent, suppression of PHGDH by Nutlin-3 can further promote 
apoptosis through ATF4-dependent Puma and Noxa activation. Meanwhile, our findings implied 
that small molecules that interrupt serine uptake may be combined with Nutlin-3 to enhance 
killing of human melanoma cells.  
Although we have uncovered that p53 can negatively regulate oncogenic serine synthesis 
pathway through transcriptional repression of PHGDH, it is still unknown whether this 
regulation pathway contributes to p53-mediated tumor suppression. Notably, transcription 
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repression of PHGDH is partially retained by p53
3KR
. Further investigations are required to 
determine if constitutive PHGDH overexpression in p53
3KR/3KR
 mice (by crossing with PHGDH 
transgenic mice) could abrogate intact tumor suppression mediated by p53
3KR
. Nevertheless, our 
study provided novel mechanistic insights into how p53 promotes apoptosis in cancer cells 
through the regulation of oncogenic serine metabolism pathway.  
Figure 5.1 
 
Figure 5.1. Proposed models demonstrating the differential effects of p53 on its apoptotic 
response through regulating PHGDH under normal condition or serine starvation.  
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5.2 Identification of SAT1 as a novel p53 target in polyamine metabolism and ferroptosis 
    Several recent studies have highlighted the importance of p53 in the regulation of cellular 
metabolism and oxidative stress response. In this study, we have provided evidence that linked 
p53 function to polyamine metabolism and ROS response through a novel metabolic target SAT1, 
an enzyme that catalyzes the rate-limiting step of polyamine catabolism. SAT1 was initially 
identified as a p53 inducible gene from RNA sequencing of p53 wild-type melanoma cells 
treated with Nutlin, a small molecular that activates p53 through inhibiting p53’s negative 
regulator MDM2. Subsequently, we revealed that SAT1 is highly inducible by both Nutlin and 
DNA damage in various cancer cell lines, and the transcriptional regulation is dependent on p53. 
This is also consistent with the previous finding that SAT1 is a highly inducible target by 
5-fluorouracil (5-FU) [173]. ChIP-qPCR analysis revealed two p53 binding sites on the promoter 
region of SAT1, indicating that SAT1 is a direct p53 target.  
    Further characterization of the functions of SAT1 was carried out in a tetracycline-inducible 
cell line expressing SAT1. Although the effects of SAT1 overexpression were previously 
described by other groups to cause a rapid cell growth arrest in Hela cells, as well as apoptosis in 
glioblastoma cells using transient transfection [138, 174], we observed neither of these 
phenomena in our inducible expression system. This may be attributable to the levels of SAT1 
being expressed in cells, as a lower expression level of SAT1 induced by tetracycline may better 
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mimic the physiological condition compared to transient transfection. Meanwhile, our xenograft 
study clearly indicated that SAT1 possesses tumor suppressive properties. Although genetic 
alterations of SAT1 gene have not been reported, both our analysis of SAT1 expression levels in 
cancer patient samples and Oncomine database demonstrated that SAT1 is significantly 
down-regulated in a variety of human cancers. This is also consistent with the fact that cancer 
cells have elevated polyamine levels. 
    Although numerous metabolic targets of p53 have been identified, it is still not completely 
understood how metabolic functions contribute to p53-mediated tumor suppression. Intriguingly, 
our recent studies have revealed that ferroptosis, an iron-dependent and non-apoptotic cell death, 
provides another layer of protection against tumorigenesis [81]. In response to inappropriate 
levels of ROS, p53 sensitizes cells to ferroptosis by transcription repression of SLC7A11, a 
component of the cystine/glutamate antiporter [81]. Nonetheless, it remains largely unknown 
how ferroptosis is regulated, and what additional targets of p53 contribute to ROS-induced 
ferroptosis. In this study, we discovered that SAT1 significantly induced lipid peroxidation and 
ferroptosis upon ROS exposure. Moreover, our data indicates that p53-mediated transcriptional 
activation of SAT1 is critical for ROS-induced ferroptosis, as knockout of SAT1 significantly 
abrogated p53-induced ferroptosis upon ROS stress. Interestingly, although SAT1 failed to elicit 
growth arrest and apoptosis, elevation of ferroptosis maker Ptgs2 was detected in xenograft 
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tumors harboring SAT1 induction. This further implies the importance of ferroptosis in 
suppression of tumor growth although future investigations are necessary to evaluate the precise 
role of ferroptosis on SAT1-mediated tumor suppression. 
    Ferroptosis is a mode of cell death that involves the production of both cytosolic and lipid 
ROS resulting from metabolic dysfunction [84, 150]. GPX4 is a glutathione peroxidase that 
catalyzes the reduction of lipid peroxides on cellular membrane. Lipid peroxidation and 
ferroptosis were observed in mouse xenografts harboring Gpx4 knockout, highlighting the 
central regulating role of GPX4 in ferroptotic pathway [150]. However, we did not observe an 
expression level change of GPX4 in SAT1-induced ferroptotic cells, nor did the overexpression 
of SLC7A11 rescue cell death. Notably, we revealed that SAT1-induced ferroptosis is dependent 
on ALOX15, a lipoxygenase that catalyzes the peroxidation of arachidonic acid (AA). Our data 
demonstrated that SAT1 increases the expression of ALOX15, and ALOX15 inhibitor can 
completely rescue SAT1-induced ferroptosis. This is also consistent with the previous finding 
that ALOX15 is the core mediator that translates oxidative stress into lipid peroxidation and cell 
death [153]. Nonetheless, although we found a correlation between SAT1 and induced expression 
of ALOX15, the precise mechanism of how SAT1 regulates ALOX15 expression is still not clear. 
Notably, it is well-known that overexpression of SAT1 would lead to depletion of spermidine and 
spermine, as well as significant increase of putrescine and N
1
-acetyl spermidine [138]. We 
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speculate that SAT1 may indirectly regulate the expression of ALOX15 through affecting the 
cellular polyamine levels. Thus, further investigations are required to explore the role of 
polyamines on transcriptional regulation of ALOX15, as well as the precise role of ALOX15 in 
modulating ferroptosis. 
Taken together, this study revealed a new p53 metabolic target SAT1 that contributes to 
p53-mediated ROS response and ferroptosis, as well as provided novel insight on the regulation 











5.3 Differential regulation of p53 transcriptional activity by acetylation 
Our identification of two novel p53 metabolic targets ultimately led to the puzzling question 
of how p53 can differentially regulate a diverse array of target genes in a context-specific manner, 
and which function contributes to tumor suppression.  
Acetylation of p53 is known to play a pivotal role in controlling promoter-specific 
activation of p53 targets. Previously, we have demonstrated that acetylation at K117/161/162 in 
mouse p53 (K120/164 in human p53) is required for the transactivation of target genes involved 
growth arrest, apoptosis, and senescence. In this study, we uncovered another two p53 
acetylation sites at lysine K101 and K139, within the human p53 DNA-binding domain, which 
are acetylated by CBP and Tip60 respectively. Both lysine residues are evolutionarily conserved 
and are homologous to lysine K98 and K136 in mouse p53. We found that ablation of acetylation 
at K98 or K136 in addition to K117/161/162 impaired the ability of p53 to activate TIGAR and 
SAT1, and repress SLC7A11. As expected, simultaneous mutation at all five acetylation sites 
(5KR: K98/117/136/161/162R) also achieved the same result. These results suggest that K98 and 
K136 acetylation are both required for the transcriptional regulation of these metabolic target 
genes. Interestingly, abrogation of acetylation at K98 or K136 alone did not affect transcriptional 
activity of p53, indicating that acetylation at K98 and K136 may have redundant roles with 
K117/161/162 in promoter-specific regulation of TIGAR, SAT1, and SLC7A11. Although our 
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discoveries further support the role of p53 acetylation in promoter-specific transcriptional 
activation, the molecular mechanism of such differential regulation is largely unknown. Notably, 









 all bind to TIGAR and SLC7A11 gene promoters to the 
similar extent, regardless of their differential transcriptional activities. One hypothesis is that the 
acetylation in the DNA-binding domain could modulate the conformation of p53, which in turn 
influences the recruitment of transcriptional machinery, co-activators, or co-repressors instead of 
affecting DNA-binding. Histone acetyltransferases (such as Tip60, CBP, p300, and PCAF) are 
often recruited by transcription factor to acetylate histones and relieve chromatin coiling 
structure to activate transcription. Therefore, it is possible that different combination of 
acetylation in the p53 DNA-binding domain allows for the recruitment of various co-activators 
and thus differentially regulates the transactivation of downstream target genes. Further 
investigations are required to elucidate the mechanism behind differential regulation by 
dissecting the co-activators or co-repressors that bind to different acetylation-deficient p53 




5.4 The roles of ferroptosis and mTOR regulation in p53-mediated tumor suppression    
The discovery of the two novel acetylation sites have broaden the scope of differential 
regulation by acetylation, and allows us to further evaluate the role of non-canonical functions in 
p53-mediated tumor suppression by comparing the tumor onset in mice harboring different 









previously described, although 3 of the 27 p53
3KR/3KR
 mice developed tumors, sequence analysis 
revealed that all of those tumor tissues obtained additional mutations in the p53
3KR
 gene [97]. 
This suggests that p53
3KR
 indeed retains intact function as a tumor suppressor. In this study, we 
found that 26 of the 36 p53
4KR98/4KR98
 mice, 6 of the 11 p53
4KR136/4KR136
 mice, and all of the 
p53
5KR/5KR
 mice (n=35) developed spontaneous tumors within 18 months of age, mainly 
including thymoma, angiosarcoma, and sarcoma. Interestingly, unlike p53
3KR/3KR
 tumors, 







 mice. This clearly indicates that loss of 
p53 non-canonical functions resulting from additional ablation of K98 or K136 acetylation could 
significantly disrupt the ability of p53 to suppress tumor formation. Notably, TIGAR, a major 
p53 metabolic target (also retained by p53
3KR
) in regulating glycolysis and antioxidant defense, 






. However, it is unlikely that this 
metabolic regulation is a major contributor to p53-mediated tumor suppression, as TIGAR, once 
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thought to mediate tumor suppression through maintaining cellular free radical homeostasis, was 







 have lost the ability to transcriptionally activate SAT1 and repress 
SLC7A11, which are two metabolic targets of p53 (also retained by p53
3KR
) involved in 






 are all defective in inducing 
ferroptotic cell death upon oxidative stress (Erastin treatment). This implies that p53-mediated 
ferroptosis may function as the last barrier to defend against tumorigenesis when growth arrest 
and apoptotic functions are absent in the p53
3KR/3KR
 mice. In fact, some previous studies have 
also supported the role of ferroptosis in regulating tumorigenesis. First, reconstitution of robust 
SLC7A11 expression in p53
3KR
 cancer cells significantly abrogated its ability to suppress tumor 
formation in xenograft mouse models [81]. Second, Ptgs2, a molecular marker of ferroptosis, 
was found to be up-regulated in the tumors when SAT1 is induced to suppress tumor growth, 
suggesting that ferroptosis is involved, at least, in part, in tumor suppression. Moreover, SL7A11 
overexpression and SAT1 down-regulation are observed in several types of human cancers.  
Nevertheless, it remains to be further elucidated regarding the link between ferroptosis and tumor 
suppression. It would be interesting to examine if blocking ferroptosis directly by using 
ferroptosis inhibitor (such as ferrostatin-1) in the p53
3KR/3KR
 mice could disrupt p53-mediate 
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mice to see if they will develop 




 mice.  





mice developed spontaneous tumors within 18 months of age, their tumor onset was significantly 
delayed for 6 months comparing with p53
5KR/5KR
 mice. This suggests that the remaining cellular 
functions that are retained in p53
4KR
 but further lost in p53
5KR
 are responsible for delaying tumor 
progression. Notably, although p53
4KR98 
has lost the ability to induce ferroptosis, it still retains 
the activity to suppress mTOR signaling through activating the expression of two mTOR 
negative regulators, Sestrin2 and DDIT4 [168, 175]. In contrast, p53
5KR
 has no activity in 
transcriptionally activation of these two targets, and it does not alter mTOR signaling either. It is 
well-known that mTOR is a central regulator of cell growth and proliferation through integrating 
a variety of cellular signaling cascades initiated by growth factors, nutrient or energy stresses, 
and regulates downstream cellular processes including protein synthesis, autophagy, and 
ribosomal biogenesis. Thus, appropriate response to these cellular stresses through mTOR can 
prevent cells from uncontrolled growth and proliferation when nutrient and energy levels are low, 
and therefore, maintain homeostasis. In fact, inappropriate activation of mTOR due to the 
deregulation of multiple elements in the mTOR pathway (such as loss of PTEN, PI3K 
mutation/amplification, AKT, S6K, and eIF4E overexpression) has been implicated in numerous 
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types of human cancers, and has been shown to contribute to tumor progression [176]. Since lack 
of nutrient, oxygen, and energy is a common phenomenon in the tumor microenvironment, it is 
likely that cancer cells insensitive to these stresses can acquire growth advantage [158]. The link 
between p53 and mTOR signaling also suggests that mTOR inhibition may be a potential novel 
mechanism by which p53 suppresses tumor progression. In fact, pharmacological inhibition of 
mTOR by rapamycin or rapamycin analogues (such as deforolimus, everolimus, and 
temsirolimus) has been efficacious in several clinical trials for the treatment of a subset of human 
cancers, and temsirolimus as well as everolimus were recently approved by FDA for the 
treatment of renal cell carcinoma, giant cell astrocytoma, and PNET (progressive endocrine 
tumours of pancreatic origin) [176-178]. Efforts in elucidating the role of mTOR inhibition in 
p53-mediated tumor suppression are still underway. We will be assessing the effect of rapamycin 
in p53
5KR/5KR
 mice by feeding them with rapamycin-containing food to determine if mTOR 
inhibition by rapamycin can delay the onset of tumorigenesis mediated p53
5KR








In summary, our studies have broadened the scope of non-canonical functions of p53. We 
first identified a novel p53 metabolic target, PHGDH, which catalyzes the rate-limiting step of 
serine synthesis. Although it is unknown whether PHGDH participates in p53-mediated tumor 
suppression, our findings provide novel mechanistic insights into how p53 promote apoptosis in 
cancer cells through the regulation of the oncogenic serine metabolism pathway. We next 
characterized another p53 target gene SAT1 in polyamine metabolism pathway, and elucidated its 
novel function in ferroptotic cell death responses and tumor suppression. Finally, we have further 
delved into the question of promoter-specific regulation of gene transcription by p53 acetylation. 
Our data revealed that two novel p53 acetylation at K101 and K139 (K98 and K136 in mouse 
p53) is crucial for differential regulation of downstream metabolic targets, and linked p53’s 
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